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INVESTIGATION OF SEASONAL REMOVAL EFFICIENCY OF 
DICLOFENAC IN A BIOLOGICAL WASTEWATER TREATMENT PLANT 
AND BIODEGRADABILITY POTENTIAL IN LAB SCALE ANAEROBIC 
REACTORS 
SUMMARY 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat 
the symptoms of pain and inflammation. Diclofenac and its metabolites excreted 
subsquently enter the ecosystem due to improper treatment in wastewater treatment 
plants and leads to toxic effects on the environmental ecology. 
This research is conducted to understand the behavior of diclofenac in wastewater 
treatment plants as well as its bidegradability potential under anaerobic conditions. 
To screen diclofenac behaviour in wastewater treatment plant, four sampling 
campaigns including summer, autumn, winter, and spring has been carried out in a 
biological wastewater treatment plant located in Istanbul. Diclofenac concentration 
in each units of wastewater treatment plant has been searched and removal efficiency 
in the wastewater treatment plant has been investigated. In addition, seasonal 
variations in diclofenac removal have been evaluated. Diclofenac concentrations in 
the plan influent have been measured as 846, 752, 1377,  and 923 ng/L in summer, 
autumn, winter, and spring, respectively. In addition, diclofenac removal efficiencies 
have been found as 51%, 12%, 27%, and %18 in summer, autumn, winter, and 
spring, respectively. Operation efficiency activated sludge process has been 
correlated with diclofenac elimination, because diclofenac removal has been 
decreased with decreasing nitrogen removal. 
The effect of diclofenac on anaerobic treatment has been studied by using anaerobic 
reactors operating in the presence of diclofenac for a long period of time.Batch 
experiments were conducted to understand the effect of initial diclofenac 
concentration, temperature, pH, and biomass concentration on its biodegradation 
potential. Parameters such as methane production, accumulation and consumption of 
xxiv 
 
volatile fatty acids (VFAs), volatile suspended solids (VSS), total suspended solids 
(SS), and dissolved organic carbon (DOC) have been used to evaluate diclofenac 
removal efficiency as well as potential inhibition. 
The behaviour of diclofenac in anaerobic bioreactors has been studied with the 
cultures developed using innoculum taken from different places. All reactors have 
been operated with 80 days sludge retention time and fed weekly with 300 and 15 
mg/L glucose and yeast extract as substrate and 10 µg/L diclofenac dissolved in 
methanol. Four main reactors called first generation reactors inoculated with river 
sediment or anaerobic digestion sludge and kept at 22ºC in mesophilic condition in 
the dark. Diclofenac removal has been obtained between the range of 13 and 31% in 
these reactors. In addition, a reactor inoculated with anaerobic digester sludge has 
been operated at 35ºC in dark to examine temperature effect and 21% diclofenac 
removal has been obtained.   
In order to understand the behaviour of diclofenac in anaerobic reactors, four 
anaerobic batch assays including different diclofenac concentrations, different 
temperature, different biomass concentration, and different carbon source have been 
performed.  
To examine the toxic effect of diclofenac on anaerobic microorganisms five batch 
reactors with different diclofenac concentrations including 0, 10, 50, 200, and 1000 
µg/L have been performed. 1000 µg/L of diclofenac concentrations has revealed very 
low inhibitory effects on methanogens that has shown itself by a decrease in methane 
production as well as in VSS concentrations.  
Also, diclofenac removal efficiencies have examined in four different temperatures 
including 10ºC, 22 ºC, 35ºC, and 45ºC. No relation has been found between 
temperature and diclofenac removal efficiency. 
 Then, the effect of biomass concentration on diclofenac degradability assessed with 
100, 75, 50, and 25 % dilution of biomass. Diclofenac removal efficiency has been 
increasing with an increasing initial biomass concentration at the first 3 days of  the 
operation.  
 Finally, different carbon source assay has been carried out by using acetate as a 
carbon source where 25% diclofenac removal has been  observed. 
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BĠYOLOJĠK ATIKSU ARITMA TESĠSĠNDE DĠKLOFENAK’IN 
MEVSĠMSEL GĠDERĠM VERĠMĠNĠN VE LABORATUVAR ÖLÇEKLĠ 
ANAEROBĠK ARITILABĠLĠRLĠĞĠNĠN ĠNCELENMESĠ 
ÖZET 
Yüksek kullanımı ve biyolojik olarak zor ayrıĢabilen yapısı nedeniyle diklofenak, 
atıksu arıtma tesislerinin çıkıĢ akımlarında, yüzeysel sularda, yer altı sularında ve 
hatta içme sularında rastlanan en önemli kirleticiler arasında yer almaktadır (Heberer, 
2002). Diklofenak sentetik bir ilaç olarak  steroid yapıya sahip olmayan 
antienflamatuar ilaçlar (NSAĠDs)  grubunda yer almaktadır. Hem insanlar tarafından 
hem de veterinerlik alanında enflamasyonu azaltmak ve ağrıyı dindirmek 
için artrit ve akut sakatlanmalarda kullanılmaktadır. Diklofenak  bir çok ülkede yıllık  
onlarca ton mertebesinde kullanılmaktadır. Dünyada yıllık 940 ton kullanımıyla 
diklofenak, en çok tüketilen steroid yapıya sahip olmayan antienflamatuar ilaçlar  
arasında bulunmaktadır (Zhang ve diğ., 2008). Ayrıca ülkemizde 2009 yılında 
satılmıĢ olan diklofenak miktarı yaklaĢık 70 ton olarak belirlenmiĢtir (IMS Health, 
2010). 
Son yıllarda diklofenak maddesinin sucul ve diğer ortamlarda görülmesi ve bu ilacın 
sucul ortamlarda yaĢayan canlılara olan olumsuz etkileri endiĢeleri arttırmıĢtır. 
Farmasötik maddelerin en toksik üyesi olarak düĢünülen diklofenak, böbrek ve 
gastrointestinal dokular üzerinde zararlı etkilere sahiptir (Haap ve diğ., 2008). Kazara 
bu kimyasala maruz kalan Asya’daki akbaba populasyonu,  yok olma tehlikesiyle 
karĢı karĢıya kalmıĢtır  (EEA, 2010). Bu nedenle diklofenak bir çok araĢtırmacı 
tarafından çevresel bir tehdit olarak öne çıkarılmaktadır (Naidoo ve diğ., 2009; Oaks 
ve diğ., 2004).  
Sucul ortamda diklofenak ekolojik toksisitesi  nispeten düĢük olmasına  ve  akut 
etkileri belirlenemeyen düzeylerde olmasına rağmen, sürekli bu ilaca maruz kalma 
durumunda canlılar üzerinde olumsuz etkileri gözlenmiĢtir.  
GökkuĢağı alabalığı (Oncorhynchus mykiss) üzerinde  yapılan kronik toksisite 
çalıĢmalarında, 28 gün boyunca 1 g/L diklofenağa maruz kalan alabalıklarda 
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karaciğer, böbrek ve solungaçlarda sitolojik değiĢikliklerin meydana geldiği 
gözlenmiĢtir. Ayrıca yapılan baĢka bir araĢtırmada 23 mg/L diklofenak 
konsantrasyonun alglerin çoğlamasını inhibisyona uğrattığı gözlenmiĢtir (Delorenzo 
ve diğ., 2008). Ayrıca 0.01-10 mg/L diklofenak konsantrasyonuna maruz kalan 
balıklarda yumurtadan çıkma  döneminde gecikme ve  yumurtadan çıkmada 
baĢarısızlık gözlenmiĢtir (Lee ve diğ., 2011).  
Geleneksel evsel atıksu arıtma tesisleri organik maddeler, azot ve fosfor gibi 
nutrientlerin giderimini gerçekleĢtirmek amacıyla aktif çamur sistemleri ile 
projelendirilmiĢtir. Diklofenak konvansiyonel aktif çamur sistemleri ile yüksek 
oranda arıtılamadığından arıtma tesisi çıkıĢ sularında ve alıcı ortamlarda ng/L ile 
µg/L seviyelerinde bulunmaktadır. 
Bu çalıĢma  Türkiye’de bulunan mevcut bir atıksu arıtma tesisinde üniteler bazında 
ve tesis bütününde diklofenak’ın mevsimsel giderimini incelemek, laboratuvar 
ölçekli yarı kesikli anaerobik reaktörlerde diklofenak’ın biyolojik arıtılabilirliğini 
araĢtırmak ve son olarak kesikli anaerobik testlerde çevresel ve iĢletme koĢullarının 
(sıcaklık, diklofenak konsantrasyonu, biyokütle konsantrasyonu ve karbon kaynağı) 
diklofenak giderimine etkisini gözlemlemek amacıyla gerçekleĢtirilmiĢtir. 
Diklofenak arıtılabilirliğini mevsimsel olarak incelemek amacıyla Ġstanbul’da 
bulunan 600000 m3/gün kapasiteli ileri biyolojik atıksu arıtma tesisinden yaz, 
sonbahar, kıĢ ve ilkbahar aylarında olmak üzere 4 defa numune alınmıĢtır. Tesis giriĢ 
akımında diklofenak konsantrasyonu yaz, ilkbahar, kıĢ ve sonbahar aylarında 
sırasıyla 846, 752, 1377, 923 ng/L olarak ölçülmüĢtür. Tesis giriĢ ve çıkıĢ 
akımlarından alınan 24 saatlik kompozit numunelerde yapılan diklofenak 
ölçümlerine göre yaz, ilkbahar, kıĢ ve sonbahar aylarında diklofenak giderimi 
sırasıyla  %51, 12, 27 ve 18 olarak bulunmuĢtur. Ayrıca karbon, azot ve fosfor gibi 
konvansiyonel parametreler incelenmiĢ ve aktif çamur sisteminin verimliliğinin 
diklofenak giderimini etkilediği de gözlemlenmiĢtir. Aktif çamur sisteminde azot 
arıtımındaki değiĢimler diklofenak giderimiyle benzer değiĢimler göstermiĢtir. Ünite 
bazında yapılan diklofenak ölçümleri neticesinde maksimum diklofenak giderimi 
anaerobik biyofosfor tankında  %32 ile %40 arasında bulunmuĢtur. 
Diklofenak’ın anaerobik koĢullar altında biyolojik arıtılabilirliğini incelemek 
amacıyla laboratuvar koĢullarında, yoğun kirliliğe maruz kalmıĢ nehir yataklarından 
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alınan sedimentler ve atıksu arıtma tesislerinin anaerobik çürütücülerinden alınan 
çamurlar aĢı olarak kullanılarak 2 L hacimli 5 adet anaerobik reaktör kurulmuĢtur. 
Reaktörler 80 gün çamur yaĢında yarı kesikli olarak çalıĢtırılmıĢtır. Reaktörler glikoz 
ve diklofenak konsantrasyonu sırasıyla 300 mg/L ve 10 µg/L olacak Ģekilde 
beslenmiĢtir. 22ºC’de çalıĢtırılan reaktörlerde diklofenak giderimi %14 ila %31 
arasında değiĢmiĢtir. Sediment etkisini azaltmak ve biyokütle aklimasyonunun 
diklofenak giderimine etkisini incelemek amacıyla reaktör içerisinden alınan 
çamurun aĢı olarak kullanıldığı ikinci nesil yeni bir reaktör kurulmuĢ ve diklofenak 
giderimi bu reaktörde %35 olarak bulunmuĢtur. 
Çevresel ve iĢletme koĢullarının diklofenak giderimine etkisini incelemek amacıyla 
laboratuvar ortamında kesikli olarak beslenen 180 mL hacimli anaerobik reaktörler 
iĢletilmiĢtir. Sıcaklık, diklofenak konsantrasyonu, baĢlangıç biyokütle 
konsantrasyonu, ve farklı karbon kaynağı olmak üzere dört farklı set kurulmuĢtur.  
Diklofenak giderimine sıcaklığın etkisini incelemek amacıyla 10, 20, 35 ve 45ºC 
olmak üzere dört farklı sıcaklıkta çalıĢılmıĢtır. Reaktörler kesikli olarak içerisinde 
300 mg/L glikoz ve 50 µg/L diklofenak konsantrasyonu olacak Ģekide beslenmiĢtir. 
10, 20, 35 ve 45ºC’deki reaktörlerde diklofenak giderimi sırasıyla %19, 19, 27 ve 22 
olarak bulunmuĢtur.  
Anaerobik reaktörlerde diklofenak konsantrasyonunun fermentativ 
mikroorganizmalar ve metanojenler üzerindeki inhibe edici etkisini incelemek 
amacıyla diklofenak konsatrasyonları 0, 10, 50, 200 ve 1000 µg/L olan  beĢ farklı 
reaktör kurulmuĢtur. Reaktörler kesikli olarak içerisinde 300 mg/L glikoz olacak 
Ģekide 22ºC’de beslenmiĢtir. Ölçümler neticesinde diklofenak gideriminin diklofenak 
konsantrasyonunun artmasıyla arttığı gözlemlenmiĢtir. Ayrıca diklofenak 
konsantrasyonu 1000 µg/L olan reaktörde diğer reaktörlere göre biraz daha düĢük 
metan üretimi gözlenmiĢtir.  
BaĢlangıç biyokütle konsantrasyonunun diklofenak giderimi üzerinde etkisini 
incelemek amacıyla % 100, 75, 50 ve 25 biyokütle içeren dört farklı reaktör 
çalıĢtırılmıĢtır. Reaktörler kesikli olarak içerisinde 300 mg/L glikoz ve 50 µg/L 
diklofenak olacak Ģekide 22ºC’de beslenmiĢtir. Ġlk 3 günde %100 ve %75 biyokütle 
içeren reaktörlerde daha yüksek giderim gözlenmiĢ ama sonrasında bütün 
reaktörlerde birbirine yakın giderim verimleri gözlenmiĢtir. % 100, 75, 50 ve 25 
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biyokütle içeren reaktörlerde sırasıyla % 26, 23, 21 ve 21 diklofenak giderimi elde 
edilmiĢtir. 
Farklı karbon kaynağı kullanımının diklofenak arıtımı üzerinde etkisini incelemek 
amacıyla karbon kaynağı olarak glikoz yerine asetatın kullanıldığı bir reaktör 
çalıĢtırılmıĢtır. Reaktör kesikli olarak içerisinde 600 mg/L asetat ve 50 µg/L 
diklofenak olacak Ģekide 22ºC’de beslenmiĢ ve bu deney neticesinde diklofenak 
giderimi %2 olarak elde edilmiĢtir. 
Çevresel ve iĢletme koĢullarının incelendiği kesikli testlerde elde edilen giderim 
verimleri karbon kaynağının reaktörde mevcut olduğu süre içinde elde edilmiĢtir. 
Karbon kaynağı reaktörde bittiğinde diklofenak konsantrasyonunda artıĢ 
gözlenmiĢtir. Bu artıĢın nedeni diklofenak’ın öncelikle mikroorganizmalar tarafından 
ara bir ürüne çevrilmesi ve ortamdaki karbon kaynağı tükendiğinde tekrar 
diklofenak’a geri dönüĢmesi olarak düĢünülmektedir. 
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1.  INTRODUCTION 
Diclofenac has been increasing concern due to its increasing presence in environment 
with rising global consumption. Diclofenac is one of the most commonly used non-
steroidal anti-inflammatory drugs (NSAID) with annually  940 tonnes global 
consumption  and  used in the treatment of arthritis, ankylosing spondylitis, and acute 
muscle pain (Zhang et al., 2008; Barbieri et al., 2012). 
Diclofenac has been identified as a problem for the water cycle because of its low 
removal rate during wastewater treatment processes (Huber et al., 2012). Recent 
studies report that the removal of diclofenac in wastewater treatment plants is often 
incomplete with treatment efficiencies ranging from less than 20–80% (Zhang et al., 
2008). As a result, the diclofenac and its metabolites excreted subsequently enter to 
the ecosystem. 
The threat of extinction in the Indian vultures due to accidental exposure to 
diclofenac in 2004 resulted in the designation of diclofenac as an environmental 
concern (EEA, 2010). The birds died because of renal failure after the consumption 
of livestock carcasses that consumed diclofenac (Oaks et al., 2004).  
Although the concentration levels detected after wastewater treatment processes 
seem not to cause toxic effects on human health and in the aquatic environment, their 
continuous release into the aquatic environment may result in long-term chronic 
exposure (Garcia-Lor et al., 2012). 
Potential toxic effects have been observed at environmentally relevant concentrations 
on aquatic organisms (Japanese medaka,  rainbow trout, and brown trout) where it 
can bioaccumulate and change cellular reactions in liver, kidney and gills(Hong et 
al., 2007; Schwaiger et al., 2004; Hoeger et al., 2005).  
The probability of biomagnification of diclofenac in the food chain ultimately in 
human requires the investigation of diclofenac treatment methods in wastewater 
treatment plants in addition to its toxicity survey. 
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The aim of this research is to investigate treatability of diclofenac in a biological 
treatment plant and in lab scale anaerobic reactors. Because diclofenac enters surface 
water via wastewater treatment plants, removal efficiency of diclofenac in existing 
wastewater treatment plant is significant subject to investigate. This research shows 
removal potential of diclofenac in existing WWTP in Turkey. 
Study related to the anaerobic treatment of diclofenac is very limited in the literature.  
Result of this research sheds light on elimination potential of diclofenac by anaerobic 
treatment processes.  
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2.  LITERATURE REVIEW  
2.1 Diclofenac 
During the last several years, pharmaceuticals that are diverse group of compounds 
designed to prevent, cure and treat disease have provoked increasing concern for 
presence of these ubiquitos, persistant and biologically active substances into water 
bodies (Ternes et al., 2007; Erickson, 2002; Heberer, 2002). In addition, 
pharmaceuticals are used in human as veterinary medicine to prevent illness; they are 
also used as growth promoters in livestock and fish farming as well as in agriculture.  
Diclofenac is a nonsteroidal anti-inflamatuary drugs (NSAIDS) belongs to one of the 
most important groups of pharmaceuticals worldwide. Diclofenac is used primarily 
for the treatment of inflammation and pain caused by conditions such as rheumatoid 
arthritis, osteoarthritis, and ankylosing spondylitis. It is also effective in treating soft 
tissue inflammations due to tendinitis and bursitis, and treating dysmenorrhea 
(menstrual cramps).  
Diclofenac is marketed  under  many brand names, such as Cataflam, Diclon, Flector 
patch, Voltarol, Voltaren, Oflam,etc  with an estimated global annual consumption  
of  940 tonnes (Zhang et al., 2008).  According to the number of prescribed defined 
daily doses (DDDs) for diclofenac (including combination preparates) amounted  in 
2006 in Netherland  (CVZ, 2007), the emission to the environment  would amount to 
approximately 6,8 tonnes/year  assuming that all prescribed  DDDs were consumed 
(DDD=100 mg, WHO, 2006) and annual consumption of diclofenac is also reported 
by another scientists as shown in Table 2.1. 
The increasing use of diclofenac causes in  problem for the water cycle due to its low 
removal rate during wastewater  treatment processes and finally results in  diclofenac 
occurance in wastewater treatment plant effluents and surface waters with 
concentrations ranging from ng/L to mg/L (Tixier et al., 2003; Andreozzi et al.,  
2003; Zorita et al., 2009). So diclofenac has started to be an environmental concern 
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due to the potential harmful effects on non-target organisms at environmentally 
relevant concentrations.   
Table 2.1 : Annual consumption of diclofenac in different countries. 
Annual Consumption 
[tonnes/year] 
Country Reference 
17.4 Spain Ortiz de Garcia et al., 2013 
6.1 Austria Calara et al., 2005 
6.8 Netherlands CVZ, 2007 
5.9 Korea Sim et al., 2010 
3.9 Switzerland Tauxe-Wuerce et al., 2005 
1 Finland Linquvist et al., 2005 
328 China Sui et al., 2010 
7.5 Germany Ternes et al., 2001 
14.9 France Metcalfe et al., 2004 
The increasing use of diclofenac causes in  problem for the water cycle due to its low 
removal rate during wastewater  treatment processes and finally results in  diclofenac 
occurence in wastewater treatment plant effluents and surface waters with 
concentrations ranging from ng/L to mg/L (Tixier et al., 2003; Andreozzi et al.,  
2003; Zorita et al., 2009). So diclofenac has started to be an environmental concern 
due to the potential harmful effects on non-target organisms at environmentally 
relevant concentrations.   
2.1.1 Characteristics of diclofenac 
Diclofenac, 2-[(2, 6-dichlorophenyl) amino] phenylacetic acid (Figure 2.1), a 
synthetic non-steroidal anti-inflammatory drug  is known as a polar molecule being 
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relatively persisent in water (Bartels et al., 2007). The physico-chemical properties of 
diclofenac are given in Table 2.2. 
 
 
 
 
 
 
Figure 2.1 : Chemical structure of diclofenac. 
Table 2.2 : Physico-chemical properties of diclofenac. 
Properties  
CAS Number 
1 
015307-86-5 
Usage 
2
 Analgesic, anti-inflammatory 
Molecular Formula 
1 
C14H11Cl2NO2 
Molecular Weight 
1 
296.16 
Water Solubility 
1 
2.37 mg/L at 25 
o
C 
Log Kow
 3 
0.7- 4.5 (pH dependent) 
Vapor Pressure 
1 
6.14E-8 mm Hg 
pKa Dissociation Constant 
1
 4.15 
Henry's Law Constant 
1
 4.73E-12 atm-m
3
/mole at 25 
o
C (estimated) 
1 SRC The Physical Properties Database 
2 Zhang et al., 2008 
3 Ternes et al., 2006 
The percentage of a compound that will be vaporized usually depends on Henry 
coefficient. Henry’s law constant of diclofenac is relatively low (H < 3E-3) to 
consider the vaporization as a potential removal alternative. 
Kow value indicates the sorption potential of the organic compounds in terms of 
hydrophobicity or hydrophility. Organic contaminants with a strong hydrophobic 
character (log Kow >4.5) were removed to a significant extent (approx. 85%), while 
hydrophilic compounds (log Kow <3.5) were poorly removed (<20%) in wastewater 
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(Sui et al., 2010). Diclofenac with its Kow value tend to remain in aqeous phase 
(Steven-Garson et al., 2011). Also compounds with low pKa such as diclofenac are 
expected to be mainly in the aqeous phase (Jones et al., 2007). 
2.1.2 Metabolites and pathways of diclofenac 
Diclofenac is used as oral administration, dermal application, eye dropping and 
injection. Zhang et al. (2008) reported that oral application is the main form of 
administration and accounted for about 70% of the worldwide diclofenac sales.  
In humans and mammals, a drug passes an initial activation reactions followed by 
conjugation reactions. After therapeutic use in humans and mammals, only 15% of 
the diclofenac is excreted as unchanged, the other part is converted to 3 and 4-
hydroxy diclofenac. Then sulphate and glutathione conjugates, in fewer quantities 
are formed via conjugation reactions (Yu et al., 2005; Sarda et al., 2011). In addition, 
Zhang et al. (2008) reported diclofenac and its metabolites in urine with a percentage 
of 65 as shown in Figure 2.2. 
 
Figure 2.2 : Metabolites of diclofenac in feaces and urine (Zhang et al., 2008). 
Parent compound and its metabolites are excreted into raw sewage and wastewater 
treatment systems. Diclofenac is mainly metabolized in humans to its hydroxylated 
or methoxylated derivatives and further conjugated,  mostly to glucuronides. These 
metabolites contains 4’-OH-DCF,  3’-OH-DCF, 5-OH-DCF, and 4’-5-diOH-DCF, 
and 3’-OH-4’methoxy diclofenac (Stülten et al., 2008). However microbial 
metabolism on conjugates may cause separation of parent compound and its 
Feacal 
metabolites
34%
DCF
6%
5-OH-DCF
6%
4'-OH-DCF
16%
3'-OH-DCF
2%
4'-5-
diOH-
DCF
10%
Others
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conjugated biomolecule that results in re-release of the biologically active drug (Jelic 
et al., 2011).   
Sewage treatment plant effluents are discharged to water bodies or reused for 
irrigation, and biosolids produced are reused in agriculture as soil amendment or 
disposed to landfill (Jelic et al., 2011). Thus, wastewater treatment plants without 
further diclofenac treatment are considered to be the primary pathway of 
pharmaceuticals to the environment (Figure 2.3).  
 
Figure 2.3 : Representative sources and fate of pharmaceuticals in the environment 
(Kummerer, 2011). 
2.1.3 Diclofenac in surface waters 
In the aquatic environment, diclofenac is one of the mostly detected at the highest 
frequency among the pharmaceuticals that are introduced into the environment 
through various ways during or after manufacturing or consumption.  Especially 
discharge of wastewater from wwtps, agricultural irrigation using wastewater, 
improper disposal of expired pharmaceuticals, use of biosolids or animal excreta to 
amend agricultural soils and, in some cases areal deposition are the main routes of 
diclofenac to contaminate surface waters (Felix-Canedo et al., 2013). Diclofenac 
8 
 
concentrations in surface waters may vary between ng/L to µg/L as shown in Table 
2.3. 
Table 2.3 : Concentrations of diclofenac in surface waters in different countries. 
Concentration 
[ng/L] 
Region Reference 
74 Spain Matamoros et al., 2013 
1030 Germany Heberer et al., 2002 
4400 Pakistan Scheurell et al., 2010 
28-32 Mexico Felix Conedo et al., 2013 
1.2-45.7 Turkey Aydın et al., 2013 
195 UK Thomas and Hilton, 2004 
16 Korea Choi et al., 2009 
2.1.4 Toxicity of diclofenac 
Diclofenac is considered as one of the most toxic type of anti-inflammatory drugs. Its 
harmful effects show itself by damaging renal and gastrointestinal tissue across 
several vertebrate taxa (Haap et al., 2008).Asian vulture populations face with near 
extinction due to the  accidental exposure (Naidoo et al., 2009). 
Almost tens millions of vultures killed in Asia because of diclofenac. Diclofenac 
causes acute renal failure and the vulture dies within a few days (Oaks et al., 2004). 
The birds became depressed at approximately 24 hour after exposure and finally 
succumbed  after 36-48 hours (Swan et al., 2006). In the last 15 years, the population 
number of three species of vultures that eat ill live stock treated with diclofenac have 
decreased more than 97%  and become endangered (EEA, 2010). 
Ecotoxicity of diclofenac is relatively low and  its acute effect also is undetectable at 
the concentration levels present in the environment. Diclofenac shows higher acute 
endpoints ranging from 47-67 mg/L that are much higher than environmentally 
relevant concentrations (Quinn et al., 2011). However combination of diclofenac 
with other drugs present in the water increases its toxic effects (Cleuvers, 2004). 
Although environmentaly relevant concentrations seem not to cause acute toxic 
effects in the aquatic organisms, chronic effects of diclofenac on aquatic organisms is 
big concern.   
9 
 
According to Schwaiger et al. (2004), continuous exposure to environmentally 
relevant concentrations of diclofenac leads to impairment of the general health of 
fishes, inducing renal lesions and alterations of the gills. A decreasing trend in 
hatching success and delay in hatch are observed in fish that exposed to 0.001–10 
mg/L of diclofenac for three months (Lee et al., 2011). On the other hand, lethality 
and teratogenicity were observed in zebra fish embryos after 96 h exposure to 
480 ± 50 μg /L (LC50/96 h) and 90 ± 20 μg /L of diclofenac (EC50/96 h), respectively 
(Dietrich et al., 1998). 
In long term toxic effect test in aquatic organisms, lowest observed effect 
concentration (LOEC) has found as 1 to 5 µg/L for rainbow trout (Schwaiger et al., 
2004) while no observed effect concentration (NOEC) has been 0.5 µg/L for brown 
trout(Hoeger et al., 2005). Further, alterations in liver, kidney and gills even at 
1 μg /L in rainbow trout have also been observed. 
Also, 15 µg/L no observed effect concentration and  30 µg/L lowest observed effect 
concentration have been found for embryos and larvae of common carp (Cyprinus 
carpio) during a 30 days toxicity test by Islas-Flores et al. (2013). 
2.1.5 Fate of diclofenac in the environment 
Diclofenac is known as a polar molecule being relatively persistent in waters with 
low volatility. The chemical properties of the substance and the observed non-
significant adsorption on suspended matter and sediments conclude that the bigger 
part of decrease of diclofenc concentration in surface waters cannot be described 
with adsorption processes. Diclofenac concentration can be decreased by photo-
transformation when exposed to the natural sunlight (Bartel et al., 2007). 
2.1.5.1 Phototransformation of diclofenac 
Diclofenac is released in considerably high amounts to the aquatic environment 
including rivers, lakes, groundwaters and seas. Several studies have shown a rapid 
decomposition of diclofenac in surface waters when exposed to natural sunlight. 
Photo-transformation or photolysis of diclofenac is one of the main degradation 
pathway in surface waters (Schulze et al., 2010). 
Bartels et al. (2007) observed that 16 days exposure to natural irradiation leads to 
decrease in diclofenac concentration. According to semi-natural laboratory tests and 
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in field experiment, it is found that sunlight stimulates the decomposition of 
diclofenac in surface waters. In summer, it is observed that diclofenac decomposition 
is increased up to 83 % in the surface layer of the water (0 to 5 cm) in Europe. 
However, the increase in water depth requires more time for decomposition of 
diclofenac.  According to the same study, at 50 cm depth 96% of diclofenac was 
decomposed in two weeeks whereas at 100 cm, 2/3 of the initial diclofenac 
concentration remained. 
Although photolysis was found to be the most important transformation pathway of 
diclofenac in surface waters leading to decomposition of up to 90% of the diclofenac 
within a few hours, photo-transformed diclofenac has been reported to be five times 
more toxic to green algae compared to the parent compound. 
Schulze et al. (2010) reported that 2-[2-(chlorophenyl) amino] benzaldehyde (CPAB) 
formed during photo-transformation product has higher toxicity than diclofenac. The 
50% effective concentration (EC50) of CPAB and diclofenac was reported as 
4.8 mg/L and 48.1 mg/L, respectively. So CPAB shows much higher toxicity than 
diclofenac due to the higher hydrophobicity of CPAB (log Kow = 3,62) compared 
with diclofenac (log Kow = 2,04) at pH 7,0. 
2.1.5.2 Fate of diclofenac in soil and sediments  
If the water that contains diclofenac is used to fertilize or irrigate crops, persistance 
and dissipation pathways of diclofenac in agricultural soil must be known. The major 
factors on diclofenac dissipation in soil are; 
 Soil type, 
 Temperature, 
 Moisture, 
 Presence or absence of biosolids. 
Diclofenac is transported  slowly in agricultural soil than the tracer in agricultural 
soil (Mersman et. al, 2002). Diclofenac  showed significant retardation under 
experimental condition in the 0-5 cm soil sample by using wastewater from wwtp 
and 68 % of diclofenac removal was achieved (Chefetz et al., 2008). 
In laboratory test by Al-Rajeb et al. (2010), diclofenac was rapidly mineralized 
without lag when added to soils varying widely in texture (sandy loam, loam, clay 
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loam). It is observed that diclofenac is readily biodegradable in agricultural soil with 
half-life less than 5 days. 
Diclofenac is carboxylic acids with pKa value of 4.16 and is negatively charged at pH 
of ambient water and sediment. Laboratory batch studies to characterize the sorption 
behavior of diclofenac in natural aquifer sediments show that sorption coefficients 
were generally quite low (Scheytt et al., 2005).  
2.1.5.3 Bioaccumulation of diclofenac 
Analysis on aquatic organisms showed accumulation of diclofenac in all organs 
related with the initial concentration of diclofenac (Schwaiger et al., 2004). For a 
concentration of 5 g/L on rainbow trout, renal lesions were evident as well as drug 
bioaccumulation was observed in the liver, kidneys, gills and muscle.  Diclofenac 
bioconcentration factors were 10–2700 in the liver of fish and 5–1000 in the kidney, 
depending on the exposure concentrations (Schwaiger et al., 2004).  
Also literature research reflects that bioaccumulation in biota or food webs are 
possible. The population of vultures significantly decreased right after the ingestion 
of diclofenac while scavenging on livestock treated with the drug (Naidoo et al., 
2009).  
2.1.6 Removal efficiency  and behaviour of diclofenac in WWTPs 
Due to their intrinsic biological activity that may cause adverse effects to aquatic and 
terrestrial ecosystems, particularly at chronic exposure, treatment of diclofenac has 
become emerging concern (Martin et al., 2012).  At present, urban wastewaters are 
considered the most important source of diclofenac to aquatic environment, because 
wastewater containing diclofenac either unchanged or metabolites originated from 
different souces such as hospitals, veterinary clinics, households and even 
pharmaceuticals manufacturing facilities reach the wastewater treatment plants to 
discharge to receiving bodies after treatment processes. 
Most of the treatment plants is operated with conventional wastewater treatment 
processes containing primary sedimentation and activated sludge system (either 
nitrification/denitrification or not) followed by final or secondary sedimentation. 
Because wastewater treatment plants have been designed to eliminate conventional 
pollutants such as organic matters, nutrients and solids, they are not capable of 
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removing diclofenac that joins wastewater via excretion or direct disposal of unused 
tablets or drops (Jones et al., 2005; Jelic et al., 2012; Suarez et al., 2008; Heberer, 
2002). 
Removal efficiencies can vary significantly from plant to plant and within a plant at 
different time periods (Vieno et al., 2007). Recent reports show that the 
concentration of diclofenac in the effluent of wastewater treatment plants reach to the 
level of µg/L as shown in Table 2.4. 
Table 2.4 : Influent and effluent diclofenac concentration in WWTPs. 
Influent 
[ng/L] 
Effluent 
  [ng/L] 
 
Region 
 
Reference 
86-580 0-120 USA Yu et al., 2013 
1400 950 Switzerland Sirbu et al., 2006 
~500 ~100 China Sui et al., 2010 
2800 1900 Germany Quintana et al., 2005 
131 24 Korea Behera et al., 2011 
1220 800 Greece Samaras et al., 2013 
905 780 Austria Clara et al., 2005 
720 530 Spain Martin et al., 2012 
1010 748 Canada Lishman et al., 2006 
58-376 25-182 Thailand Tewari et al, 2013 
2133 1617 Germany Bernhard et al., 2006 
Activated sludge processes are used in most of the wastewater treatment plants in 
order to mineralize the pollutant to water and carbon dioxide by microorganisms and 
degrade them into acceptable forms before discharging to the receiving bodies. In 
addition to these processes, pollutants can also be removed by stripping into air or by 
sorption onto sludge through the process. Some studies reveals that elimination of 
diclofenac in municipal wastewater treatment plants with activated sludge process is 
often incomplete with treatment efficiencies ranging between 9% and 62% as shown 
in Table 2.5. 
Removal efficiencies of diclofenac in wastewater treatment plants are variable 
depending on the compound specific properties as well as factors related to the 
treatment processes factors such as the type of treatment process employed, 
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operational conditions of the treatment process (e.g., temperature, redox conditions, 
solids retention time and hydraulic retention time), and the climate conditions (e.g., 
temperature and sunlight intensity) (Castiglioni et al., 2006; Le-Minh et al., 2010).   
Table 2.5: Removal efficiency of diclofenac in wwtps with activated sludge process. 
Flow rate 
[m
3
/day] 
Removal  
[%] 
Region Treatment  
Process 
Reference 
650000 39 Greece CAS Samaras et al., 2013 
350000 33 Thailand CAS with A/O Tewari et al, 2013 
60000 27 Germany - Bernhard et al., 2006 
62000 26 Spain CAS Martin et al., 2012 
42000 41 Spain CAS Gracia-Lor et al., 2012 
- 20-40 Switzerland CAS with A/O Jones et al., 2005 
30000 21 Korea CAS with A2/O Sim et al., 2011 
- 9-25 Finland - Lindqvisk et al., 2005 
40000 35 Italy CAS Verlichi et al., 2013 
9300 0 Switzerland CAS Tauxe et al., 2005 
27250 62 Spain CAS Matamoros et al., 2013 
CAS: Conventional activated sludge process; A/O: continuous flow suspended growth process with 
anoxic and oxic stages; A2/O: continuous-flow suspended-growth process with anaerobic, anoxic, and 
oxic stages. 
Elimination of pharmaceuticals or its metabolites occurs in activated slugde 
processes at four mechanisms including biodegradation, sorption, air stripping and 
phototransformation (Zhang et al., 2008).  
According to Poseidon (2006), the removal of diclofenac by air stripping is limited 
due to its low Henry coefficient (Table 2.1). Therefore, air stripping is omitted from 
the removal mechanism of diclofenac. Two processes are mainly responsible for the 
removal of pharmaceutical compounds: biodegradation and sorption onto sludge. 
Diclofenac can be transformed from the aqueous phase by biotransformation or by 
sorption to primary and secondary sludges (Le-Minh et al., 2010). 
Diclofenac is classified under the poor biodegradable compounds with a 0.1 L/kg 
SS.day  first order degradation rate constant (Joss et al., 2006).  Lee et al. (2012) 
tested biodegradability of diclofenac by activated sludge and found no 
biodegradation through the 28 days without any significant change.  
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Similarly, the transformed percentage of diclofenac in a batch biodegradation study 
employing a similar methodology during 50 days incubation period resulted in 30% 
removal efficiency (Yu et al., 2006)  and slow biodegradation was reported using 
other biological reactors by other researchers (Zwiener and Frimmel, 2003; 
 González et al., 2006). Quintana et al. (2005) investigated the biodegradation of 
diclofenac by activated sludge. They found no transformation of diclofenac over 28 
days incubation period, neither when diclofenac was the sole source of carbon, nor 
when it was dispersed in milk powder. 
Kow value  shows hydrophobic or hydrophilic character of the compound to 
understant the tendency of compound to remain on aqeous phase or to sorp onto 
sludge. Organic contaminants hydrophilic compounds (log Kow <3.5) were poorly 
removed (<20%) by sorption mechanism (Gasperi et al., 2010).  The pharmaceuticals 
with low Kow values and low pKa values as diclofenac are mainly detected in 
wastewater instead of in sludge (Martin et al, 2012). However, diclofenac has partial 
biodegradability in activated sludge systems (Joss et al., 2006; Quintana et al., 2005) 
The efficiency of diclofenac removal in the activated sludge is increased with high 
sludger retention time (SRT) that allows for the enrichment of slowly growing 
bacteria and formation of more diverse group of microorganisms capable of 
degrading wide range of pollutants. However, it is reported that diclofenac removal 
is not dependent with SRT ranging from 3 to over 30 days in a study conducted in 
several wastewater treatment plants (Lishman et al., 2006). In addition, Kreuzinger et 
al. (2005) did not found any correlation between diclofenac removal and SRT (up to 
300 days). 
2.2 General Information About Investigated Wastewater Treatment Plant 
In order to investigate seasonal diclofenac removal efficiency, sampling campaigns 
have been carried out in a biological wastewater plant located in Istanbul. 
Wastewater treatment plant serves 2 400 000 people by operating with a 400 000 
m
3
/day advanced biological treatment capacity and a 600 000 m
3
/day pre-treatment 
capacity. 
Wastewater treatment plant collect the wastewater from some districts of the Istanbul 
through collectors, to convey such wastewater to the wastewater treatment plant, 
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where the wastewater is treated in advanced level by treatment processes such as 
coarse and fine screens, primary sedimentation, biological treatment, secondary 
sedimentation for wastewater; thickening, anaerobic digestion, dewatering and 
drying for sludge as shown in Figure 2.4. 
 
 
Figure 2.4: Investigated advanced biological wastewater treatment plant. 
2.2.1 Preliminary treatment 
Wastewater reach to the plant first transferred through coarse screens with 50 mm 
spacing that is designed to protect the plant structure against large solid particles 
could create obstructions in the facility’s units as well as negative affect for 
efficiency of treatment process. Wastewater pumped from the inlet pumping station 
passes through mechanically cleaned fine screens with 10 mm spacing.  
Then wastewater enters to grit retaining chambers (6 chambers) each with 2 troughs. 
Grit chambers in the plant separate the grit and inorganic material up to 0.20 mm 
grain diameter by diffused air, while at the same time separate minerals and organic 
particles within the grit trap thus operational problems such grit sedimentation in 
aeration tanks and digesters, increased wear of equipment is prevented.  
Wastewater from grit chambers follows through two primary sedimentation tanks 
which are large enough that settlable particles can settle and floating materials such 
as grease can rise to surface and be skimmed off thus both homogenous liquid 
capable of being treated biologically and settled sludge are obtained. Primary 
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sedimentation tanks generally equipped with mechanically driven scappres that 
continually drive the collected sludge towards a hopper in the base of the tank. 
2.2.2 Biological treatment 
Biological treatment is achieved by 5-stage Bardenpho system with 2 bio-
phosphorous tanks, 2 oxic tanks where nitrification takes place and 2 anoxic tanks 
where denitrification occurs. Anoxic and oxic conditions are adjusted by diffusers in 
the tanks. 
56% of wastewater fed into the aerated tank and wastewater come from primary 
sedimentation enters into 3 biological phosphorous tanks, which are operated in 
parallel. Anaerobic ambient conditions are met during the biological treatment.  
Treatment system is based on the removal of carbon, nitrogen by flows through 
aerated (aerobic) and non-aerated (anoxic) tanks subsequently. Biological treatment 
system consists of 3 aeration tanks operating in parallel. The tanks are designed to 
ensure a continuous flow. 2-stage supply method is chosen due to improper 
carbon/nitrogen ratio. This way, the carbon source in the wastewater is distributed 
step by step. In this system, the SS density in the BioP Tank and first stage tanks is 
high, which optimizes the total volume of tanks. Activated sludge/wastewater 
mixture leaving the biological phosphorus unit enters the denitrification and 
nitrification tanks at the first section. At each stage, internal circulation is ensured by 
means of internal return pumps. Phosphorus, nitrogen and carbon are removed at the 
outlet of the biological unit. 
Wastewater from aeration tanks are collected in distribution units and then enters to 
the final sedimentation tanks which are equipped with semi-rotary bridge scrappers 
operated continuously. Bottom scrappers convey the settled sludge to the sludge 
collecting zone while surface scrappers on the rotary bridges convey the scum on 
surface to the scum collecting chamber. 
2.2.3 Sludge treatment 
Primary sludge with 1083 m
3
/day flow rate and excess sludge with 14 000 m
3
/day 
flow rate flow through nine centrifugal sludge thickeners. With such centrifuges, the 
ratio of solid particles increase to 6 % and sludge are pumped to sludge digesters. 
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Sludge digesters consists of 6 cylinders made of reinforced concrete, each with a 
volume of 10 000 m
3
. At such tanks, sludge stabilization is achieved under anaerobic 
conditions, resulting in a sludge volume decrease and biogas generation. Average 
detention period of the sludge in the digester is 16 days and average temperature is 
35-37⁰C. The biogas is stored in two gas tanks. Further, the stabilized sludge is 
stored in the sludge storage tank for 1 hour and pumped to sludge dewatering unit.  
Sludge is dewatered by centrifuges (in total 6 centrifuges) to increase suspended 
solid ratio from 6 % to 25%.   
Sludge with 25 % suspended solid ratio is dried to become 90 % in drying unit after 
dewatering process.   
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3.  MATERIALS  AND METHODS 
3.1 Sampling From  Wastewater Treatment Plant 
In this study, four sampling campaigns have been carried out in July 2012, 
November 2012, March 2013 and May 2013 to investigate diclofenac removal 
efficiency in different treatment units as well as to characterize seasonal changes in 
diclofenac concentrations. In the treatment plant, sampling of both mixed liquor and 
sludge samples were performed from 10 different sampling points as shown in 
Figure 3.1. Sampling types and dates in each season are shown in Table 3.1. 
Table 3.1: Sampling dates and types. 
Sampling 
Points 
Summer 
Campaign 
July 2012 
Autumn 
Campaign 
November 2012 
Winter 
Campaign 
March 2013 
Spring 
Campaign 
May 2013 
Mixed Liquor     
Influent Composite Composite Composite Composite 
Grit chamber Grab - Grab - 
Primary clarifier Grab - -* - 
Anaerobic tank Grab - Grab - 
Anoxic tank Grab - Grab - 
Oxic tank Grab - Grab - 
Final clarifier Grab - Grab - 
Effluent Composite  Composite Composite Composite 
Santrate Grab - Grab - 
Sludge     
Primary sludge Grab - -* - 
Secondary sludge Grab - Grab - 
Digester sludge Grab - Grab - 
Dried sludge Grab - Grab - 
*Primary clarifier was not in operation in winter campaign.
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Figure 3.1: Sampling points in wastewater treatment plant.
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In summer and winter campaigns, 24 hour composite samples from plant influent and 
effluent; grab samples from grit chamber effluent, primary clarifier effluent, 
anaerobic tank, anoxic tank, oxic tank, secondary clarifier effluent were taken as 
mixed liquor. In addition to this, grab sludge samples were taken from primary 
clarifiers, secondary clarifiers, anaerobic digesters, thickeners and drying unit. While 
24-hour plant influent sample has been collected from effluent of grit chamber, 24-
hour plant effluent sample has been collected from effluent of secondary clarifier.  
In spring and autumn campaigns, samples were only collected form influent and 
effluent of wastewater treatment plant as 24-hour composite samples. 
Samples were collected in fluorinated jerricans with a total volume of 10 L (Thermo 
Scientific) and transported to the laboratory in coolers. 1 L of samples have been 
preserved in amber bottles  and  acidified  with 1 N hydrochloric acid (HCl) for 
chemical oxygen demand, total Kjeldahl nitrogen, total organic carbon and total 
phosphorous analysis while 1 L of samples has been reserved as unacidified form for 
other analyses (i.e., pH, total suspended solids, volatile suspended solids and 
ammonia). 
 
Figure 3.2 : Storage of samples with teflon coated jerricans and amber glass bottles. 
About 2 L of samples have been immediately centrifuged for 15 min at 10000 rpm in 
500 mL teflon centrifuge tubes and then filtered using 0,22 µm filters (Millipore). 
Filtered wastewater has been kept in the amber glass bottles as shown in Figure 3.2. 
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All samples have been preserved in 4
º
C refrigerator. Sludge samples have been 
preserved at -20
º
C after centrifuge. Sludge samples have been dried under vacuum in 
freeze drier (Thermosavant) before diclofenac measurement. 
As soon as samples have been taken, analysis of the samples has been started 
immediately. All analyses have been performed within one week. 
3.2 Anaerobic Reactors Set Up 
In order to investigate biodegradability potential in anaerobic conditions, semi-batch 
reactors have been performed in laboratory. Pressure resistant glass reactors with 
volumes changing between 2,5 L and 6 L have been filled with weighted or 
measured amount of inoculum. Then, three openings in the reactors were closed with 
teflon caps, teflon stoppers and valves (Figure 3.3).  
Each reactor has been flushed with pure N2 gas under 1-2 psi for 30 minutes to 
provide anaerobic conditions by replacing oxygen gas with nitrogen.  After flushing, 
each reactor has filled with anaerobic media to the desired level to provide 42-52 % 
empty headspace in the reactors. Then decided amount of substrate (glucose and 
yeast extract) and diclofenac were added to reactor. Reactors have been operated in 
the dark and mixing has been achieved with magnetic stirrers. 
 
Figure 3.3 : Configuration of anaerobic reactors. 
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3.2.1 Anaerobic media 
10 L of pressure resistant glass bottle (Simax, Czech Republic) has been used for 
media preparation.  The silicone cap with two pipes mounted on the glass bottle for 
feeding and flushing purposes has been autoclaved under high pressure and 
temperature to sterilize materials for avoiding microbial activity. Chemicals used in 
the media preparation that are essential for microbial growth are shown in Table 3.2. 
Table 3.2 : Constituents of anaerobic media. 
Component Concentration 
K2HPO4 0.9 g/L 
KH2PO4 0.5 g/L 
NH4Cl 0.5 g/L 
CaCl2∙2H2O 0.1 g/L 
MgCl2∙6H2O 0.2 g/L 
FeCl2∙4H2O 0.1 g/L 
Trace Metal Stock Solution 1 mL/L 
Resazurin Stock Solution 2 mL/L 
Vitamin Stock Solution 0.2 mL/L 
NaHCO3 1.2 g/L 
Na2S∙9H2O 0.5 g/L 
 
To prepare metal stock solution, chemicals shown in Table 3.3 have been weighted 
and added to 1 L of volumetric flask and completed to 1 L with deionized water (DI). 
Then it has been transferred to amber glass bottle and preserved at 4
º
C in refrigerator. 
Table 3.3 : Constituents of trace metal stock solution. 
Component Concentration, g/L 
ZnCl2 0.5 
MnCl2∙4H2O 0.3 
H3BO3 3 
CoCl2∙6H2O 2 
CuCl2∙2H2O 0.1 
NiSO4∙6H2O 0.2 
Na2MoO4∙2H2O 0.3 
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In order to prepare resazurin stock solution, 100 mg resazurin has been weighted and 
transferred to 100 mL of volumetric flask and completed with deionized water to 
abtain 1 g/L solution (Table 3.4). Prepared solution has been transferred to amber 
glass bottle and  preserved at 4 
º
C in refrigerator. 
Table 3.4 : Constituents of resazurin stock solution. 
Component Concentration 
Resazurin 1 g/L 
To prepare vitamin stock solution, chemicals shown in Table 3.5 have been weighted 
and added to 1 L volumetric flask. After transferred to amber glass bottle, it has been 
preserved at 4
o
C in the refrigerator. 
Table 3.5 : Constituents of vitamin stock solution. 
Component Concentration, g/L 
Biotin 0.2 
Folic Acid 0.2 
Pyridoxine Hydrochloride 1 
Riboflavin 0.5 
Thiamine 0.5 
Nicotinic Acid 0.5 
Pantothenic Acid 0.5 
Vitamin B12 0.01 
p-Aminobenzoic Acid 0.5 
Thioctic Acid 0.5 
 
8 L glass bottle graduated with 2 L intervals have been filled with distilled water to 6 
L and chemicals have been added into bottles for 8 L (7.2 g K2HPO4; 4 g KH2PO4, 4 
g NH4Cl; 0.8 g CaCl2∙2H2O; 1.6 g MgCl2∙4H2O; 0.8 g FeCl2∙6H2O; 8 mL of trace 
metal stock solution and 16 mL of resazurin stock solution). 
Prepared solution has been completed to exceed (~ 200 mL) 8 L taking into account 
the losses during the evaporation. Solution has been heated with continuous mixing 
until it boiled (Figure 3.4). After ten minutes boiling, cap with pipes has been sealed 
and vanes have been placed into pipes to provide impermeability of gas. Oxygen gas 
has been replaced with nitrogen gas while the media is still hot by flushing the media 
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bottle for 30 minutes with pure N2 gas. Flushing also facilitated the cooling of the 
media. 
Na2S∙9H2O (4 g) have been injected to media to provide reduced condition. After 
media has been cool down, 9.6 g NaHCO3 and 1.6 mL of vitamin stock solution has 
been added into media bottle by transferring with a syringe under anaerobic 
conditions. 
 
 
Figure 3.4 : Preparation of anaerobic media. 
3.2.2  Anaerobic culture development 
3.2.2.1 Culture developed at 22ºC 
Reactor A.I, B.I, C.I, D.I, and E.I have inoculated with 80 g Alibeyköy river 
sediment (Eyup, Istanbul), 200 mL of anaerobic digestion sludge from an advanced 
biological wastewater treatment plant-1, 80 g of Kağıthane river sediment (Sisli, 
Istanbul), 80 g of America river sediment (Bayou d’Inde, LA, USA) and 750 mL of 
anaerobic digestion sludge from a wastewater treatment plant-2, respectively. Glass 
reactors with a total volume of 3650 mL have been flushed with nitrogen gas under 
1-2 psi pressure after decided amount of sludge was placed into the reactor. Then, 
reactors have been filled with anaerobic media until 2 L as shown in Figure 3.5. 
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These five main reactors have been the first generation anaerobic reactors due to 
direct inoculation with sediment or anaerobic digestion sludge. 
 
Figure 3.5: First generation anaerobic reactors at 22 
º
C. 
Reactor A.I, B.I, C.I, D.I, and E.I have been inoculated at 22
º
C in dark with 80 day 
SRT. To provide 80 day of SRT 350 mL of sludge has been drawn off from each 
reactor and then reactors recompleted up to 2 L with anaerobic media every 14 days. 
Reactors have been fed weekly with glucose and yeast extract to provide 300 mg/L 
and 15 mg/L concentrations in the reactors, respectively. Reactor A.I, B.I, C.I, and 
D.I have been amended with diclofenac in methanol weekly to provide 10 µg/L 
diclofenac concentrations (40 µL from 500 mg/L diclofenac stock solution in 
methanol). Diclofenac stock solution has been prepared into methanol du to 
diclofenac’s low solubility. Diclofenac is dissolved in a solvent such as methanol 
tointroduce the culture. Reactor E.I has been operated as control reactor without 
diclofenac addition. However, 40 µL of methanol has been added to Reactor E.I 
weekly to compensate extra carbon coming from diclofenac stock solution in 
methanol in other reactors.  
In order to eliminate the sediment that may be originated from the innoculum, 
another reactor as second generation (Reactor A.II) have been  installed using  
inoculum from Reactor A.I. 100 mL of inoculums  have been placed into reactors 
and closed with teflon caps and teflon stoppers. After 30 minutes flushing with 
nitrogen gas, reactor filled with media until 2 L (Figure 3.6). The reactors were 
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operated at 22ºC in the dark with the amendment of 1 µg/L diclofenac, 200 mg/L 
glucose, and 15 mg/L yeast extract. In order to maintain 80 day SRT, 350 ml of 
sludge have been replaced with anaerobic media every 14 days.   
 
Figure 3.6 : Reactor A.II and A.III operated at 22
º
C 
A third generation (Reactor A.III) culture was also initiated with the innoculation of 
270 ml sludge from Reactor A.II as a third generation anaerobic reactors.  After 
flushing, it has been filled with anaerobic media until 4 L (Figure 3.6). It was 
operated  at 22ºC in the dark with 1 µg/L diclofenac and 200 mg/L glucose and 15 
mg/L  yeast extract concentration. In order to maintain 80 day SRT, 700 ml of sludge 
was replaced with anaerobic media every 14 days. Reactor A.III which is the third 
generation mixed culture has been used as a sediment-free culture source for all 
batch assays. 
3.2.2.2 Culture developed at 35ºC 
100 mL culture inoculum taken from anaerobic digestion sludge of a wastewater 
treatment plant-2 has been  placed  into reactor  to build Reactor F. Reactor bottle 
with a total volume of 2420 mL have been sealed with teflon caps, teflon stoppers 
and valves and flushed with nitrogen gas under 1-2 psi.  
After flushing, reactor was filled with anaerobic media until 1.4 L. Reactor F has 
been performed at 35 
º
C in continuously stirred incubator (Thermoforma, orbital 
shaker) (Figure 3.7). It has been operated in the dark with 80 day SRT. Every 14 
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days, 245 mL of sludge has been discharged from reactor and refilled up to 1.4 L 
with anaerobic media to sustain 80 day SRT. Reactor F have been fed weekly with 
glucose, yeast extract and diclofenac to provide 300 mg/L, 15 mg/L and 10 µg/L 
diclofenac concentrations in the reactor. 
 
Figure 3.7 : Reactor F.I in incubator at 35 
o
C. 
All reactors have been mixed mechanically everyday and gas production, gas 
composition, pH, volatile fatty acids (VFA) concentration, and dissolved organic 
carbon concentration have been followed to observe microbial activity in each 
reactor summarized in Table 3.6. 
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Table 3.6: Summary of anaerobic reactors. 
 
              Reactor Generation number 
      
          Inoculum Diclofenac Concentration 
[µg/L] 
        Temperature 
[
o
C] 
A.I 1
st
 Alibeyköy river 
sediment 
10 22 
B.I 1
st
 Anaerobic digestion 
sludge of a WWTP-1 
10 22 
C.I 1
st
 Kağıthane river sediment 10 22 
D.I 1
st
 America river 
Sediment 
10 22 
E.I 1
st
 Anaerobic digestion 
sludge of a WWTP-2 
- 22 
F.I 1
st
 Anaerobic digestion 
sludge of a WWTP-2 
10 35 
A.II 2
nd
 Anaerobic culture 
from A.I 
1 22 
A.III 3
rd
 Anaerobic culture 
from A.II 
1 22 
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3.3 Anaerobic Batch Assays Set Up 
Pressure resistant glass serum bottles with a total volume of 245 mL have been 
sealed with teflon lined stoppers. Serum bottles have been flushed for 20 min at 1-2 
psi with N2 gas to provide anaerobic conditions by replacing oxygen gas with 
nitrogen. Then, a total of 180 mL culture and anaerobic media has been transferred 
anaerobically with 60 mL syringes and decided amount of substrate (glucose and 
yeast extract or acetate) and diclofenac was added. 
3.3.1 Different initial diclofenac concentration assay 
Batch assay has been conducted to investigate the effect of diclofenac concentration 
on anaerobic microorganisms and methanogenic activity. Six culture series have 
been prepared in 245 mL of serum bottles with different diclofenac concentrations 
including 0 µg /L (Control 1 and 2), 10 µg /L (Set 1a), 50 µg /L (Set 1b) , 200 µg /L 
(Set 1c), and 1 mg/L (Set 1d), respectively (Figure 3.8).  
 
Figure 3.8 : Anaerobic reactors with different diclofenac concentrations. 
Serum bottles have been sealed tightly with teflon lined stoppers (Wheaton, USA) 
and anaerobic conditions have been provided by flushing bottles for 20 minutes with 
nitrogen gas at 1-2 psi. Serum bottles have been filled with appropriate amount of 
anaerobic media and culture from Reactor A.II and Reactor E.I indicated in Table 3.7 
by syringe anaerobically.  
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Table 3.7 : Matrix of anaerobic batch assay with different initial diclofenac concentrations. 
  1 200 + 10 g/L glucose and YE; 2 18 mg/L diclofenac in MeOH; 3  90 mg/L diclofenac in MeOH; 4 360 mg/L in MeOH; 5 1.8 g/L diclofenac in MeOH. 
 
 
Reactor 
E.I 
Culture 
Reactor A.II 
  Culture 
 
Anaerobic 
Media 
Glucose 
+ 
YE
1
 
 
MeOH 
Diclofenac 
in MeOH 
Stock I.A
2
 
Diclofenac 
in MeOH 
Stock I.B
3
 
Diclofenac 
in MeOH 
Stock I.C
4
 
Diclofenac 
in MeOH 
Stock I.D
5
 
 
Control 1 
 
 
60 mL 
 
 
- 
 
 
120 mL 
 
 
270 µL 
 
 
100  µL 
 
 
- 
 
- 
 
- 
 
- 
 
Control 2 
 
 
60 mL 
 
 
60 mL 
 
 
60 mL 
 
 
270 µL 
 
 
100  µL 
 
 
- 
 
- 
 
- 
 
- 
Set 1a 
(10 µg/L 
diclofenac) 
 
 
60 mL 
 
60 mL 
 
60 mL 
 
270 µL 
 
 
- 
 
100  µL 
 
 
- 
 
- 
 
- 
Set 1b 
(50 µg/L 
diclofenac) 
 
 
60 mL 
 
 
60 mL 
 
 
60 mL 
 
 
270 µL 
 
 
- 
 
- 
 
 
100 µL 
 
 
- 
 
- 
 
Set 1c 
(200 µg/L  
diclofenac) 
 
 
60 mL 
 
60 mL 
 
60 mL 
 
270 µL 
 
 
- 
 
- 
 
- 
 
100  µL 
 
 
- 
Set 1d 
(1 mg/L 
diclofenac) 
 
 
60 mL 
 
60 mL 
 
60 mL 
 
270 µL 
 
 
- 
 
- 
 
 
- 
 
- 
 
 
100  µL 
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Two serum bottles have been prepared for each culture series. One of them has been 
used for liquid samping whereas the other one has been used for gas sampling. All 
serum bottles have been kept at 22ºC in dark and shaken manually once a day. 
Diclofenac concentrations for each culture series have been provided by adding same 
amount of stock solutions in methanol (100 µL) that prepared separately for each 
culture series. Because methanol coming from the stock solution is a carbon source 
for microorganisms, same amount of methanol has been also added to each reactor. 
Due Control 1 and Control 2 culture series have been fed without diclofenac 
addition, 100 µL methanol has also been injected into them.  
Each serum bottles have been amended with glucose and yeast extract to sustain 300 
and 15 mg/L concentrations, respectively. Thus, 1000 mg/L COD has been 
introduced to serum bottles by adding methanol and glucose.  
Gas production and composition, diclofenac, VFA, DOC, pH and ORP parameters 
have been measured to investigate microbial activity. 
3.3.2 Different temperature assay 
Batch assay has been conducted to investigate temperature effect on the 
biodegradation of diclofenac in anaerobic condition. Four culture series with their 
control have been prepared in 245 mL of serum bottles in different temperatures 
including 10
º
C (Set 2a), 20 
º
C (Set 2b), 35
º
C (Set 2c), and 45
º
C (Set 2d).  
Serum bottles have been sealed tightly with teflon stoppers and flushed for 20 min at 
1-2 psi with N2 gas to provide anaerobic conditions by replacing oxygen gas with 
nitrogen. Then, a total of 180 mL culture and anaerobic media has been transferred to 
serum bottles anaerobically with 60 mL syringes (Table 3.8).  
Each culture series have contained one control that has consisted of 180 mL of 
anaerobic media to observe the degradation potential of diclofenac in abiotic 
conditions at four different temperature. To eliminate microbial contamination, 
sterilized syringes and needles have been used for preparation and sampling of 
abiotic controls. 
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Table 3.8 : Experimental setup to assess the temperature effect on diclofenac 
degradation under anaerobic conditons. 
 1 200 + 10 g/L glucose and YE; 2 90 mg/L diclofenac in MeOH. 
5 serum bottles have been prepared for each culture series. One of them has been 
used for gas sampling, two of them have been used for liquid sampling of first 
feeding cycle, the others have been used for liquid sampling of second feeding cycle.  
Before the addition of glucose, yeast extract and diclofenac, all culture series have 
been incubated for the acclimation at their respective temperature for one day. 
100 µL of diclofenac stock solution in methanol have been injected to all serum 
bottles except controls to sustain 50 µg/L concentrations. Controls have been 
amended with 100 µL of methanol to balance the substrate in terms of methanol. All 
serum bottles amended with glucose and yeast extract to provide 300 mg/L and 15 
 
 
Raector 
E.I 
Culture 
 
Reactor 
A.III 
Culture 
 
Anaerobic 
Media 
Glucose 
+ 
YE
1
 
Diclofenac 
in MeOH 
Stock 
2
 
Serum 
Bottles 
Set 2a 
(10 
o
C) 
 
 
40 mL 
 
70 mL 
 
70 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x5) 
Set 2a  
Control 
(10 
o
C) 
 
- 
 
 
- 
 
 
180 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL 
 (x1) 
Set 2b 
(20 
o
C) 
 
 
40 mL 
 
 
70 mL 
 
70 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x5) 
Set 2b  
Control 
(20 
o
C) 
 
- 
 
 
- 
 
 
180 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x1) 
Set 2c 
(35 
o
C) 
 
 
40 mL 
 
 
70 mL 
 
70 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL 
 (x5) 
Set 2c  
Control 
(35 
o
C) 
 
- 
 
 
- 
 
 
180 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x1) 
Set 2d 
(45 
o
C) 
 
 
40 mL 
 
 
70 mL 
 
70 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x5) 
Set 2d  
Control 
(45 
o
C) 
 
- 
 
 
- 
 
 
180 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 mL  
(x1) 
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mg/L concentration, respectively. Thus, 1000 mg/L COD has been introduced to 
serum bottles by adding methanol and glucose. 
10
o
C (Set 2a) , 20 
o
C (Set 2b), 35
o
C (Set 2c) and 45
o
C have been performed at 10
o
C 
refrigerator, room temperature, 35
o
C incubator (Thermoforma, orbital shaker) and, 
45
o
C incubator (Memmert) in dark as shown in Figure 3.9. All serum bottles have 
been shaken manually or mechanically once a day. 
 
Figure 3.9 : Anaerobic batch assay reactors with different temperatures. 
Gas composition and production, diclofenac, VFA, DOC, pH and ORP parameters 
have been measured to investigate microbial activity at different temperatures. 
3.3.3 Different biomass concentration assay 
A batch assay has been conducted to investigate the effect of biomass concentrations 
on the biodegradation of diclofenac under anaerobic condition. Different biomass 
concentrations including 100 % (Set 3a), 75 % (Set 3b), 50 % (Set 3c) and 25 % (Set 
3d) have been performed into 245 mL of serum bottles with same diclofenac 
concentration.  
Serum bottles have been sealed tightly with teflon stoppers, then anaerobic 
conditions have been provided by flushing serum bottles with nitrogen gas at 1-2 psi. 
Anaerobic media, culture from Reactor A.II and Reactor E.I have been transferred to 
serum bottles to provide decided amount of biomass as shown in Table 3.9.  
 
35 
 Table 3.9 : Experimental set up to assess the biomass concentration effects on   
diclofenac biodegradation under anaerobic conditions. 
1 200 + 10 g/L glucose and YE; 2 90 mg/L diclofenac in MeOH.. 
       Three serum bottles have been prepared for each culture series. Two of them 
have been used for liquid samping whereas the other one has been used for gas 
sampling. All serum bottles have been kept at 22ºC in dark and shaken manually 
once a day. 
All culture series have been amended with glucose, yeast extract, and methanol to 
provide 300 mg/L, 15 mg/L and 50 µg/L concentrations, respectively. Thus, 1000 
mg/L COD has been introduced to serum bottles by adding methanol and glucose. 
3.3.4 Different carbon source assay 
In this batch assay, acetate was used instead of glucose to examine the effect of a 
different carbon source on diclofenac biodegradation.  
Serum bottles have been sealed  tightly with teflon stoppers and flushed for 20 min at 
1-2 psi with N2 gas to provide anaerobic conditions by replacing oxygen gas with 
nitrogen. 60 mL of culture from Reactor A.II, 60 mL of culture from Reactor E.I, and 
60 mL of anaerobic media have been transferred to serum bottles anaerobically with 
60 mL syringe. 
 
 
Reactor 
E.I 
Culture 
Reactor 
A.II 
 Culture 
 
Anaerobic 
Media 
Glucose 
+ 
YE
[1]
 
Diclofenac 
in MeOH 
Stock 
[2]
 
Serum 
Bottles 
Set 3a 
(100 % of 
biomass) 
 
 
90 mL 
 
90 mL 
 
0 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 
mL ( x3) 
Set 3b  
(75 % of 
biomass) 
 
 
67.5 mL 
 
67.5 mL 
 
 
45 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 
mL ( x3) 
Set 3c 
(50 % of 
biomass) 
 
 
45 mL 
 
45 mL 
 
90 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 
mL ( x3) 
Set 3d 
(25 % of 
biomass) 
 
 
22.5 mL 
 
22.5 mL 
 
 
135 mL 
 
 
275 µL 
 
 
100  µL 
 
 
245.8 
mL ( x3) 
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3 serum bottles have been prepared during the experiment. One of them has been 
used for gas sampling, the others one have been used for liquid sampling for 
consecutive two feeding cycles. 
Diclofenac in methanol and acetate have been injected to each serum bottles to 
provide 50 µg/L and 600 mg/L concentrations, respectively. Thus, 1000 mg/L COD 
has been introduced to serum bottles by adding methanol and acetate. 
All culture series have been kept at 22ºC in dark and shaken manually once a day. 
Gas composition and production, diclofenac, VFA, DOC, pH and ORP parameters 
have been followed. 
3.4 Analyses 
3.4.1 Analytical methods 
3.4.1.1 pH 
pH was conducted using pH/milivolt meter (ThermoOrion) as shown in Figure 3.10 
with calibration for each measurement. Probe was celeaned and dried for each 
sample then inserted into the sample. Data was recorded after ready sign was seen. 
3.4.1.2 Oxidation reduction potential (ORP) 
ORP was conducted using pH/milivolt meter (Thermo Orion) by replacing pH probe 
with ORP probe (Orion). The meter and electrode output periodically calibrated 
using an ORP reference solution (Light solution: 1 M ferrous ammonia sulphate, 0,1 
M ferric ammonium sulphate, and 1 M sulfuric acid). The difference between the 
meter ORP reading and the theoretical value of reference solution (455 mV at 25ºC) 
has been taken into account in all measurements. Probe was cleaned and dried for 
each sample then inserted to sample that was taken immediately before the 
measurement. Electrode was fitted tightly in the bottle filled with sample. Data was 
recorded after ready sign was seen. 
3.4.1.3 Total gas production 
Gas measurement has been conducted by using monometer (Lutran, PM-9107) that 
performs measurement between 0 and 7000 mbar (Figure 3.11). Meaurement in mbar 
unit has been converted to mL unit by using Equation 3.1.  
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𝑃  𝑚𝐿 =
𝑃  𝑚𝑏𝑎𝑟 ∗ 𝑉ℎ × 𝑉
0 × 106
𝑅 × 𝑇
        (3.1) 
Vh: Head space volume in the reactor (L), 
V
0
: Molar volume of gas at relevant temperature (K), 
R : Ideal gas constant (L.atm/mol.K) 
T: Temperature (K) 
 
Figure 3.10 : Manometer. 
3.4.1.4 Gas chromatography 
Flame ionization detection 
Volatile fatty acids concentrations  including acetic, propionic, iso-butyric, butyric, 
iso-valeric, valeric  have been measured by using gas chromatography (Agilent 
Technologies, 6890N) equipped  with a flame ionization (FID) detector  and 
capillary column (DB-FFAP 125-3232).  
For the VFA analysis, the temperature of the injection port and detector have been  
230°C and 250°C, respectively. The sample has been injected with splitless injection 
The oven temperatue have reached 100°C in first 5 minutes and then 160°C; it has  
been kept at this temperature for 5 minutes and fixed at 230°C in 3 minutes. Column 
has been operated with helium as the carrier gas at a constant flow rate of 4 mL/min 
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In VFA analyses, 1.6 mL of sample filtrated from 0.22 µm membrane filter has been 
transferred to 2 ml HPLC vial and then 20 µL phosphoric acid (10 N) has been 
added. VFAs in the vials have been quantified in gas chromatoraphy (GC). 
Thermal Conductivity Detection 
Gas chromatography (Agilent Technologies, 785CA) has been equipped with two 
columns and two thermal conductivity detectors have been used to measure gas 
composition. Methane, nitrogen has been separated with CPT530 column (Agilent 
Technologies) and carbon dioxide has been separated with HP-PLOT/Q column 
(Agilent Technologies) column. Both columns have been operated with helium as the 
carrier gas at a constant flow rate of 6 mL/min. The 10:1 split injector has been 
maintained at 150ºC, and the detector temperature has been set at 150ºC. All gas 
analyses have been performed by injecting 100 µL gas sampe while detectors’ 
temperature was set to 150
o
C. 
3.4.1.5 Total Kjeldahl nitrogen (TKN) 
Total Kjeldahl nitrogen experiment has been occured in three steps; digestion 
included decompisition of organic nitrogen to ammonia, distillation 
includedcollection of condensed nitrogen in boric acid and titration. 
Sample volumes decided according to Table 3.10 was placed into 800 mL Kjehldal 
flasks and completed to 300 ml with distilled water. Kjeldahl flasks have been placed 
into digestion part  of  TKN set (Gerhardt, Germany) that designed to remove acid 
steams  after 50 mL digestion solution and a few boiling chips have been added into 
it. Boiling has proceeded until approximately 30 minutes after white fumes have 
been observed to obtain 25 – 30 mL light green solution in Kjeldahl flask. 
After cooling, light green solution has been diluted to 300 mL distilled water and 50 
mL neutralization solution  has been added into flasks. Subsequently, erlenmayers 
have filled with 50 mL boric and Kjeldahl flasks have been placed into distillation 
part of TKN set and nitrogen in the Kjeldahl flasks has been distilled into boric acids 
in the erlenmayers. Then samples in the erlenmayers have been titrated with 0.02 N 
H2SO4 solution until light purple colour has been obtained after 2 drops of mixed 
indicator is added. 
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Table 3.10 : Samples volumes for TKN according to Standard Methods. 
Organic-N in Samples 
[mg/L] 
Sample Volume 
[mL] 
0-1 500 
1-10 250 
10-20 100 
20-50 50 
50-100 25 
3.4.1.6 Ammonia 
Ammonia nitrogen experiment has been occured in two steps; distillation included 
collection of condensed nitrogen in boric acid and titration. 
Sample volumes decided according to Table 3.11 have been   placed into 800 mL 
Kjeldahl flasks and completed to 500 ml with distilled water. Kjeldahl flasks have 
been placed into distillation part of TKN set after 25 mL borate buffer and a few 
boiling chips have been added into it.  
Table 3.11 : Sample volumes for ammonia according to Standard Methods. 
Ammonia-N in Samples 
 [mg/L]   
Sample Volume 
[mL] 
5-10 500 
10-20 100 
20-50 50 
50-100 25 
Subsequently, erlenmeyers have filled with 50 mL boric acid solution ang Kjehldal 
flasks have been placed into distillation part of TKN set and nitrogen in the Kjehldal 
flasks have been distilled into boric acid in the erlens. Then samples in the erlens 
have been titrated with 0.02 N H2SO4 solution until light purple colour has been 
obtained after 2 drops of mixed indicator is added. 
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3.4.1.7 Total phosphorous 
Micro-Kjeldahl flasks have been filled with 5 mL of samples. 1 mL of concentrated 
sulfuric acid and 5 mL of concentrated nitric acid have been added into flasks with a 
few boiling chips and Kjeldahl flasks have placed into digestion part of TKN set. 
Boiling has been proceeded until 1ml sample remaining in the flasks. After cooling, 
25 mL of distiled water has been added into flasks. Concentrated sulphuric acid and 
1 N sodium hydroxide have been used to adjust pH.  Sample in the flask has been 
tranferred to 100 mL volumetric flask by filtering and completed  to 100 mL with 
distilled water. 4 ml of ammonium molybdate and 0.5 mL of tin chloride have been 
added into volumetric flask. Samples have been transferred to cell and measured in 
spectrophotometer at 690 nm wavelength between 10 and 12 minutes after tin 
chloride has been added.  
3.4.1.8 Chemical oxygen demand 
COD measurements have been performed as described in the ISO 6060 Method.. 
COD tubes filled with 2.5 ml of samples have been put in 1,5 mL of potassium 
dichromate digestion solution. 3.5 mL of sulphuric acid reagents have been also 
added to tubes as catalyst. COD tubes have been sealed tightly and placed into COD 
digester at 150
o
C for 2 hours. 
After 2 hour digestion and cooling to the room temperatures, samples have been 
transferred to conical flask. Samples have been titrated with ferrous ammonium 
sulfate until reddish colours have been observed after 2 drops of ferroin indicator has 
been added. 
3.4.1  General methods 
3.4.1.1 Diclofenac measurement in aqueous phase 
Diclofenac in aqueous phase has been measured in three steps; solid phase extraction 
that diclofenac has been extracted with solvent from cartridge diclofenac captured in, 
evaporation  that only diclofenac has been obtained by evaporation of extracting 
solvent, and measurement in LC-MS/MS after dissolved diclofenac with methanol 
has been filled into a vial. 
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Vacuum manifold with 20 sampling ports (VocMaster, Biotage) used to place Oasis 
HLB cartridges (6 cc, 200 mg;  Waters, Millford) for solid phase extraction as shown 
in Figure 3.11. Sample volumes introduced to the cartridges have been decided 
according to estimated diclofenac concentrations existed in sample. 100 ml and 1 – 
10 mL samples filtered from 0.22 µm PVDF filter (Chromafil) have been used for 
WWTPs samples and anaerobic reactors’ samples, respectively. 
 
Figure 3.11 : SPE of reactor samples. 
Initially cartridges have been conditioned with 5 + 5 mL of acetonitrile  (Merck),  5 
mL of methanol (Merck) and 5 mL of distilled water (DI) (Merck). Then decided 
amount of samples have been introduced to the cartridges at flowrate of 3.5 
mL/minutes after  d4-diclofenac (isotopically labelled diclofenac) has been added to 
samples as internal standards for measurement in LC-MS/MS. After sample loading, 
cartridges have been washed with 5 mL of water and dried under vacuum for 60 min, 
and then have been eluted with 2 mL of acetonitrile and 2 mL of methanol as shown 
in Figure 3.12.  
Subsequently, extracts have been evaporated at 35 
º
C, under 10  bar N2 flow in 
Turbovap II (Caliper Life Sciences, USA) as shown in Figure 3.13.  
Diclofenac remained in the Turbovap tubes has been reconstructed with 1 mL 
MeOH–water (10:90, v/v) and placed into vial to be measured in LC-MS/MS after 
filtering with 0.22 µm filter. Samples have been analyzed using a Thermo Electron 
Cooperation TSQ Quantum Access triple quadruple mass spectrometer coupled with 
Accela Ultra Performance Liquid Chromatograph (UPLC). 
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Figure 3.12 : Schematic diagram of diclofenac measurement in aqueous phase. 
43 
 
Figure 3.13 : Evaporation of samples in Turbovap. 
3.4.1.2 Diclofenac measurement in sludge phase 
0.1 g of  sludge samples  dried  at freeze dry (ThermoSavant, Modulyo D) under 
vacuum and have been weighted and placed into teflon centrifuge tubes. 10 mL of 
methanol-acetone (1:1, v/v) has been added into sludges after injection of d4-
diclofenac. To provide transition of diclofenac from sludge to solvent 10 minutes  
ultrasonic bath (Intersonik, MIN12) has been applied (Figure 3.14).  
Soon after, supernatants have been separated after centrifuging at 9000 rpm for 15 
minutes. Then 10 mL methanol- acetone has been added again into teflon tubes and 
ultrasonic bath and centrifugation have been applied with the similar conditions as 
shown in Figure 3.15. 
 
Figure 3.14 : Ultrasonic bath. 
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Figure 3.15 : Schematic diagram of diclofenac measurement in sludge phase. 
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First and second supernatants have been collected and placed into evaporator tubes 
and evaporated to dryness at 45 
º
C at evaporator (Heidolph, Laborota 4000) and 
dissolved with a mixture of 2 mL methanol-acetone and 18 ml water. Subsequently, 
solid phase extraction has been applied without d4-diclofenac addition. 
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4.  RESULTS AND DISCUSSIONS 
4.1 Characterization and Diclofenac Removal in wwtp 
4.1.1 Summer Campaign 
Sampling for summer campaign has been carried out in dry weather conditions in 
July 2012.  In total 12 samples including 24 hours composite influent and effluent 
samples have been collected from different units of wastewater treatment plant. 
Conventional characterization of the samples has been performed by monitoring the 
parameters such as COD, TKN, NH3, TP, etc.  in all samples and showed in Table 
4.1. 
The pH throughout the units has been varied between 7.0 and 7.9 without further 
change. COD concentration of plant influent has been measured as 865 mg/L in 24 
hours composite sample.  This value has been decreased to 26.9 mg/L in plant 
effluent by achieving 96 % COD removal in the plant. The ratio between COD and 
soluble COD has been found as 24 % at the influent of the plant. According to 
measurement in 24 hour composite samples, soluble COD has decreased from 205 
mg/L to 25 mg/L with 88% of removal yield. 
TOC and DOC measurement have been also performed in the samples. The ratio 
between TOC and DOC has been found as 30 % at the influent of the plant. 
According to measurement in 24 hour composite samples from influent and effluent, 
94% and 86% of removal yield have been obtained for TOC and DOC, respectively. 
TKN and NH3 concentration in the 24 hours influent sample have been measured as 
73 and 36 mg/L, respectively. Throughout the plant, 92% of TKN removal has been 
observed while TKN concentration has decreased to 5.94 mg/L for 24 hours 
composite sample taken from the effluent of the plant. Also, 95% of NH3 removal 
has been observed while NH3 concentration has decreased to 2.24 mg/L that has been 
measured in 24 hours effluent sample. 
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Table 4.1 : Conventional characterization results of WWTP in summer campaign (July 2012). 
a 24 hours composite samples; b Grab samples. 
 
Sample pH TSS 
 (mg/L) 
VSS 
(mg/L) 
TOC 
 (mg/L) 
DOC 
(mg/L) 
COD 
(mg/L) 
sCOD 
(mg/L) 
TKN 
(mg/L) 
NH3-N 
(mg/L) 
TP 
(mg/L) 
Influent
a
 7.5 630 ± 5 380 ± 4.7           240  72 865 ± 6 205.7 ± 5 73.92 36.96 10.99 
Grit Chamber
b 7.8 510 ± 30 350 ± 4.7 220 ± 4 53 425± 12 155.1 ± 5 87.47 47.60 9.65 
Primary Clarifier
b
 7.9 180 ± 20 155 ± 20  102.18 29 360 ± 56 170 ± 5 62.44 36.40 7.88 
Anaerobic Tank
b
 7.1 10920 ± 50 6110 ± 40 2750 ± 258 595 7520 ± 111.9 25 ± 5 477.40 28.00 40.74 
Anoxic Tank
b
 7.2 8660 ± 250 4900 ± 225 1968 ± 362 517 4510 ± 111.9 20.6 ± 6.7 395.92 22.40 35.80 
Aerobic Tank
b
 7.7 8780 ± 30 4980 ± 60 2047 ± 223 496 4895 ± 111.9 20.6 ± 5 118.16 14.00 24.69 
Final Clarifier
b
 7.7 4 2 16,48 10 39.6 ± 2.2 19.0 ± 4.8 3.78 0.98 5.65 
Effluent
a
 7.9 10 9 14.72 9.7 30 ± 4.5 25.3 ± 6.7  5.94 2.24 3.28 
Primary Sludge
b 7.7 57400 ± 495 24000 ± 141 13402 ± 1940 - 33554 ± 859 - 1668.80 140.00 397.53 
Secondary Sludge
b
 7.0 3680 ± 42 2125 ± 7 1205.40 - 3560 ± 559.5 - 256.48 33.60 170.37 
Digestion sludge
b
 7.4 37575 ± 459 14625 ± 813 9180 ± 2992 - 10760 ± 895 - 1936.48 974.40 646.91 
Santrate
b
 7.6 10630 ± 42 5580 ± 57 3324 106 7120 ± 223.8 234.2 ± 4.5 977.76 627.20 383.95 
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In addition, TKN and NH3 concentration in grab samples of grit chamber have been 
87 and 48 mg/L, respectively. Activated sludge process has achieved almost 
complete removal of TKN and NH3 providing removal efficiency of  94% and 97%, 
respectively that has resulted in 3.78 mg/L of TKN and 0.98 mg/L of NH3 in final 
clarifier effluent.  
According to measurements in 24 hours composite samples from influent and 
effluent of the treatment plant, a decrease in the total phosphorous concentration was 
observed from 10.99 mg/L to 3.28 mg/L with 70% of removal efficiency.  
Diclofenac concentration in 24 hours composite influent sample has been measured 
as 846.39±57.65 ng/L as shown in Figure 4.1. Higher concentration has been 
observed such 1058, 64±86 ng/L in grit chamber effluent that collected as grab 
samples. The reason of this has been variations in pollution load during the 24 hours 
in composite sample. 51 % of diclofenac removal efficiency has been observed while 
diclofenac concentration has decreased to 412.90±43.21 ng/L in the plant effluent.  
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Figure 4.1 : Diclofenac concentration in each unit of WWTP in summer campaign 
(July, 2012). 
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Diclofenac removal efficiency has been investigated for primary treatment and 
secondary (biological) treatment by using grab samples. It is observed that 21% of 
diclofenac removal has been achieved in primary treatment. Similar to this value, 
maximum removal efficiency in primary treatment has been found by Behera et al. 
(2011) as maximum 28%. Due to low Kow, diclofenac has insignificant adsorption 
potantial to particles removed in primary treatment. Most of the removal efficiency 
(approximately 45%) has been observed in secondary treatment. Similar to our 
findings, it is reported that 28–53% of diclofenac, has been removed by secondary 
treatment in the wastewater treatment plants (Sui et al., 2010). 
Diclofenac measurement has been also performed in the sludge phase of each 
sample, but negligible amount has been detected as 36.87±9.81 ng/g as shown in 
Table 4.2. Diclofenac has not been detected in the sludge samples where diclofenac 
has beem measured. Similar to our study, in a study performed in Japan they have 
found the diclofenac concentration in the sludge samples in the range of 6-29 ng/g 
(Matsou et al., 2011). It has been reported by several authors that removal of 
diclofenac from wastewater has been achieved by biodegradation instead of sorption 
onto sludge (Nakata et al., 2006; Jones et al., 2005; Martin et al., 2012).   
Table 4.2 : Diclofenac concentrations in sludge samples. 
Sampling point Diclofenac Concentration 
[ng/g]* 
Primary Sludge < 5 
Anaerobic Tank  < 5 
Anoksik Tank  < 5 
Aerobic Tank 36.87±9.81 
Secondary Sludge < 5 
Anaerobic Digester Sludge < 5 
Santrate < 5 
Dried Sludge < 5 
             
*
Dried weight basis. 
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4.1.2 Autumn Campaign 
Sampling for the characterization study in autumn has been carried out in November 
2012. 24 hours influent and effluent composite samples collected from the effluent of 
grit chamber and final clarifier, respectively. Conventional parameters such as COD, 
TKN, NH3, TP, etc. have been measured in all samples and showed in Table 4.3. 
450 mg/L of COD has decreased to 110 mg/L in plant effluent by achieving 76% 
COD elimination in the overall processes. The ratio between total COD and soluble 
COD has been found as 61% at the influent of the plant. 89% of soluble COD 
removal has been observed by decreasing 275 mg/L in plant influent to 30 mg/L in 
plant effluent. 
Table 4.3 : Conventional caharacterization results of WWTP in autumn campaign 
(November 2012). 
Parameter Unit Influent Effluent Removal 
pH - 8.20 7.82 - 
COD   mg/L 450±60 110±30 76 
sCOD  mg/L 275±5 30±5 89 
TOC   mg/L 310±124 47±6 84 
DOC  mg/L 95±0.01 26.3±5.6 94 
TSS  mg/L 350±5 20±5 - 
VSS mg/L 250±5 15±5 - 
TKN mg/L 84.5±0.24 46 45 
NH3-N mg/L 53.03±0.24 40.6±0.3 24 
TP mg/L 84±1.8 2.2±0.2 74 
 
TKN and NH3 concentration in the influent sample have been measured as 84.5 and 
53.03 mg/L. Throughout the plant, 45% of TKN removal has been observed while 
TKN concentration has decreased to 46 mg/L that has been measured in 24 hours 
effluent sample. 23% of NH3 removal has been observed while NH3 concentration 
has decreased to 40.60 mg/L which has been measured in 24 hours effluent 
composite sample. Also 73% removal has been achieved for total phosphorus by a 
decrease from 8.37 mg/L to  2.22 mg/L. 
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Diclofenac concentration in plant influent sample has been measured as 856.92±62 
ng/L. 36% diclofenac removal efficiency has been observed while diclofenac 
concentration has decreased to 545.55±33 ng/L in the plant effluent. Removal of 
diclofenac has been reported as within the range of 40% in wwtps depending on the 
configuration and operation condition of WWTPs as well as wastewater 
characteristics (Zhang et al., 2008).  
4.1.3 Winter Campaign 
Sampling has been carried out in March due to continuous precipitation in winter 
season. A total of ten samples including 24 hours influent and effluent composite 
samples have been collected. Conventional parameters such as COD, TKN, NH3, TP, 
etc. have been measured in all samples and showed in Table 4.4. 
The pH have been observed between 7.0 and 8.0 in all samples taken from ten units 
of the plant. 638 mg/L of COD have been measured in 24 hour composite sample of 
plant influent. It has decreased to 79 mg/L in plant effluent by achieving 88% COD 
elimination in the plant. The ratio of soluble COD to total COD has been found as 
20% at the influent of the plant. 81% of sCOD removal has been observed by 
decreasing 128 mg/L in plant influent to 24 mg/L in plant effluent. 
TOC and DOC measurements have been also performed to investigate carbon 
removal. According to measurement in 24 hour composite samples of effluent and 
effluent, 60% of diclofenac removal yield have been obtained for TOC. TKN 
concentration in the plant influent have been measured as 83 mg/L. Throughout the 
plant, 24% of TKN removal has been observed while TKN concentration has 
decreased 63 mg/L that has been measured in the plant effluent.  
In addition, TKN and NH3 concentration in grab samples of grit chamber have been 
83 and 44 mg/L, respectively. Activated sludge process has achieved 29% and 25% 
of TKN and NH3 elimination by reaching  54 mg/L of TKN and 47  mg/L of NH3 in 
final clarifier effluent concentrations.  
According to measurement in 24 hours composite samples of influent and effluent, 
total phosphorous concentration has decreased from 7.57 mg/L to 3.49 mg/L with 
55% removal efficiency. In activated sludge process 83% of removal efficiency has 
achieved for phosphorous which has been decreased from 7.6 mg/L in primary 
clarifier effluent to 1.41 mg/L in final clarifier effluent.  
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Table 4.4 : Conventional characterization results of WWTP in winter campaign (March 2013). 
Numune Adı pH TSS  
(mg/L) 
VSS 
(mg/L) 
TOC 
(mg/L) 
DOC  
(mg/L) 
COD 
(mg/L) 
sCOD 
(mg/L) 
TKN  
(mg/L) 
NH3-N 
(mg/L) 
TP  
(mg/L) 
Influent
a
 7.5 673±9 358±7 80±13 47.68 638±0 128±2 83.08±0.6 44.63 7.57±0.1 
Grit Chamber
b
 8.0 536±5 331±12 93±9 58±10 786±21 134±4 89.55±16 63.09 7.6±0.1 
Anaerobic Tank
b
 7.0 11416±24 7833±0 591 134±8 9371±0 43±2 759.40±107 53.51 120±22 
Anoxic Tank
b
 7.3 5363±5 3626±9 565 143.8±40 3942±736 37±4 390.73±56 50.22 72.5±.2.6 
Aerobic Tank
 b
 7.2 5133±47 3483±71 422 85±13 3867±210 15±2 419.24±11 49.16 69.6±1.1 
Final Clarifier
b
 7.5 33±4 26±0.7 30±0.1 20±2.2 56±4 13±0 54.04±4 47.30 1.41 
Effluent
a
 7.5 59±4 44±0.7 32±0.6 22±0.03 79±2 24±2 63.80±4 50.30 3.49±0.1 
Secondary Sludge
b
 7.0 12025±177 8200±71 450±140 389±11 7719±0 -  961.38±17 64.97 190.1±8.7 
Digestion sludge
b
 7.4 32800±141 16550±71 1163±18 230±45 24049±1259 321±2 2616±125 1134.84 539.5±75 
  a24 hours composite samples; b Grab samples. 
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Figure 4.2 : Diclofenac concentration in each unit of WWTP in winter campaign 
(March, 2013). 
In the influent of the wastewater treatment plant based on the 24 hours composite 
sample, the diclofenac concentration have been detected as 1376±486 ng/L as shown 
in Figure 4.2. Higher concentration has been observed (i.e., 1431±164 ng/L) in grit 
chamber effluent that has been collected as grab samples. The reason of this has been 
the variations in pollution load during the day. 
27% of diclofenac removal efficiency has been observed while diclofenac 
concentration has decreased to 1012±39 µg/L in the plant effluent. It is reported that 
diclofenac was not completely removed during wastewater treatment process with 
20-30% of removal efficiency (Suarez et al., 2008). During secondary treatment, 
30% of removal yield has been obtained from measurements conducted using grab 
samples. According to a research, 28–53% of diclofenac was removed by secondary 
treatment in the conventional wastewater treatment plant (Tauxe-Wuershe et al., 
2005). 
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4.1.4 Spring Campaign 
Spring sampling has been carried out in May 2013. 24 hours composite samples have 
been collected from wwtp influent and effluent. Conventional parameters such as 
COD, TKN, NH3, TP, etc. have been measured in two samples and showed in Table 
4.5. 
758 mg/L of COD has decreased to 53.6 mg/L in plant effluent by achieving 93% 
COD elimination in the overall processes.The ratio between COD and soluble COD 
has been found as 23% at the influent of the plant. 77% of TOC removal has been 
observed by decreasing 230 mg/L in plant influent to 53.6 mg/L in plant effluent. 
Table 4.5 : Conventional characterization results of wwtp in spring campaign  
                   (May 2013).  
Parameter Unit Influent Effluent* Removal 
pH - 7.66 7.91 - 
COD   mg/L 758±32 53.6±4.2 93 
sCOD  mg/L 174±6.3 44.6±8.4 74 
TOC   mg/L 230±18 88.9±5.8 77 
DOC  mg/L 143±3.01 53.6±4.2 38 
TSS  mg/L 408±11 119 ± 45 - 
VSS mg/L 248±45 86±31.3 - 
TKN mg/L 97.6±1.6 47.6±0.17 51 
NH3-N mg/L 55.98±0 36.25±0.29 35 
TP mg/L 9.22±0.68 1.9±0.069 79 
       
*
30 minutes settling has been applied in laboratory conditions. 
TKN and NH3 concentration in the influent sample have been measured as 97.6 and 
55.98 mg/L. Throughout the plant, 51% of TKN removal has been observed while 
TKN concentration has decreased to 47.6 mg/L that has been measured 24 hours 
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effluent sample. Also, 35% of NH3 removal has been observed while NH3 
concentration has decreased to 36.25 mg/L that has been measured 24 hours effluent 
sample. Also, 79% phosphorous removal has been obtained. 
Diclofenac concentration in plant influent sample has been measured as 923±31 
ng/L. The removal of diclofenac has been observed as 18 % with 756±9 ng/L 
diclofenac concentrations in the plant influent and effluent. Lower treatment 
efficiencies has been found in literature even Tauxe-Wuerch et al. (2005) has pointed 
also no elimination in wastewater treatment plants in Switzerland.  
Higher diclofenac concentration has been measured in winter as shown in Figure 4.3. 
It has been related to higher consumptions of drugs during the cold period of the 
year. Inflow loads during winter time have been reported two times higher than loads 
during summer (McArdell et al.,  2003).   
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Figure 4.3 : Diclofenac removal efficiency and concentrations in influent and 
effluent.  
Maximum diclofenac removal yield has been observed in summer season as shown 
in Figure 4.3.  In summer season, conventional parameters such as COD, TKN, NH3,  
and TOC have shown better removal efficiency with 96, 92, 94, and 90% removal 
with respect to other seasons. The seasonal differences of pharmaceuticals 
concentration in the treated effluents have seemed to reflect the performance of 
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treatment processes. These compounds have been more effectively removed in 
warmer temperature of summer in the presence of abundant sunlight (Yu et al., 
2013).  
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Figure 4.4: Removal efficiencies of diclofenac, COD, TOC, TKN, and TP. 
Diclofenac removal efficiency has shown similar trend with COD during a year. 
Higher removal efficiency for diclofenac has been observed in summer while lower 
elimination has been observed in autumn. Also, COD has shown declining trend in 
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autumn. Positive correlations have been found by Santos et al. (2009) through the 
association of these compounds to the dissolved organic matter present in wastewater 
which is commonly characterized by BOD and COD values. 
Activated sludge efficiency has been related with diclofenac removal efficiency 
because most part of the diclofenac elimination has been achieved in secondary 
treatment processes. By secondary treatment, 45% of diclofenac removal has been 
achieved in summer wheraes 28% of diclofenac removal has been obtained in winter. 
TKN and NH3 removal efficiencies that indicates activated sludge process’ 
performace have been higher in summer resulting in higher diclofenac elimination  
with respect to other seasons. Diclofenac removal efficiency has decreased in other 
seasons with decrease in TKN and NH3 removal. Lower diclofenac elimination has 
been obtained in autumn where lowest TKN and NH3 efficiencies have been found 
with respect to other seasons. 
4.2 Anaerobic Culture Development 
4.2.1 Cultures developed at 22ºC 
Culture series were developed under fermentative-methanogenic conditions to 
investigate the effect of diclofenac on fermentation, methanogenesis and diclofenac 
biodegradation. First generation anaerobic batch reactors including Reactor A.I, B.I, 
C.I, and D.I reactors have been operated  for  a long time with same diclofenac (10 
µg/L) and substrate concentration (300 mg/L glucose and 15 mg/L yeast extract). 
Inoculum characteristics are shown in Table 4.6. 
Table 4.6 : Characteristics of sludges and river sediments used as inoculums. 
*
dry matter. 
 
Inoculum     pH TS 
 [%] 
VS 
[%] 
TOC  
[mg/g]
*
 
Alibeyköy river sediment 7.35 63.71 ± 0.60 4.58 ± 0.26 18.36 
AD sludge of WWTP-1 7.39 6.78 3.85 11.30 
Kağıthane river sediment 7.22 51.60 ± 1.99 5.63 ± 0.00 22.04 
America river sediment 6.15 41.99 35.05 48.72 
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During the operation the pH has been remained in the neutral range (6.0-7.0), and the 
ORP has been observed nearly in the range of -200 and -330 mV in all reactors  
(Table 4.7). 
Table 4.7 :  pH and ORP values of Reactor A.I, B.I, C.I, and D.I. 
Reactor       pH ORP [mV] 
       A.I 7.19 ± 0,30     -210 
       B.I 7.22 ± 0,30     -330 
       C.I 7.31 ± 0,28     -215 
       D.I 7.09 ± 0,38     -253 
 
Reactors A.I, B.I, C.I and D.I have been fed weekly with 350 mg/L COD consisted 
of glucose and methanol. Theoretically 329, 338, 333, and 348 mL of biogas 
production have been expected by Reactor A.I, B.I, C.I, and D.I with methane 
percentage of 73, 71, 72, and 69 that has been measured in GC (Table 4.8). 
While lower biogas production have been observed in all of the reactors at the 
beginning of the acclimation period due to acclimation and development of 
microorganisms in the new conditions, biogas production has been increased in the 
following feeding cycles. 
Table 4.8 : Biogas composition and theoretical gas production of Reactor A.I, B.I, 
C.I, and D.I. 
 
Reactor 
CH4 
[%] 
CO2 
[%] 
Theoretical Biogas 
Production 
[mL] 
A.I 73 27 329 
B.I 71 29 338 
C.I 72 28 333 
 
Biogas production profiles of reactors shows that, Reactor A.I, B.I, and C.I have 
been performed better biogas  production trends with respect to Reactor D.I (Figure 
4.5).  
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Figure 4.5 : Biogas production of Reactor A.I (A), B.I (B), C.I (C), and D.I (D). 
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While Reactor A.I, B.I, and C.I have shown increasing biogas production 
performance along the feeding period, Reactor D.I has not revealed stable biogas 
production performance despite 160 days long operation time.  
Reactor A.I, B.I, and C.I have not reach their theoretical biogas concentration and 
produced 265, 267 and 240 mL of biogas, respectively. Diclofenac may be the cause 
of depletion in biogas production with a loss of 19, 21, 28% in Reactor A.I, B.I, and 
C.I, respectively. 
Biogas production of Reactor D.I has been varied for every feeding cycle. pH of the 
reactor have tended to decresase but it has been adjusted to 7 with the addition of 
NaHCO3 (0.5 g/L).  
Reactor A.I and C.I have been examined in terms of volatile fatty acids that were 
converted from substrate by fermentative microorganisms for one feeding cycle. As 
shown in the Figure 4.6, volatile fatty acids including acetic acid and propionic acid 
have been both produced and then consumed by microorganisms in the reactors and 
participated in biogas formation. 
Reactor A.I , B.I, and C.I have been fed weekly with diclofenac by providing 10 
µg/L diclofenac concentration in each feeding cycle during 52 days. During 52-day 
operation period, averagely 20, 21, and 36.8 % of diclofenac removal have been 
achieved in Reactor A.I , B.I, and C.I, respectively. 
The reason why high elimination has been observed in Reactor C.I can been the high 
particulate matter content which comes from the inoculum,where diclofenac can be  
adsorbed. It also explained the decrease in diclofenac removal after two weeks in this 
reactor.  
After the day 52, the feeding with both carbon source and diclofenac in Reactor A.I , 
B.I, and C.I have stopped. Although the reactor has not been fed with additional 
carbon source between the day 52 and 121, diclofenac being a potential carbon 
source has not biodegraded in the reactor. Although, no carbon source has been 
present in the reactor except than diclofenac, diclofenac removal was not observed.  
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Figure 4.6 : Volatile fatty acids formation in the Reactor A.I (A) and C.I (B). 
Reactor D.I has been fed weekly with diclofenac to provide 10 µg/L diclofenac 
concentration. A decrease in diclofenac concentration have been observed after five 
feeding cycle but due to the lack of proper biogas performance or methanogenic 
activity, the removal rate of diclofenac in the Rector D.I has been very low averagely 
12%. 
At the end of the operation diclofenac elimination has been achieved as 31, 20, 30 
and 13 % in Reactor A.I, B.I, C.I, and D.I, respectively (Figure 4.7).  
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Figure 4.7 : Theoretical and measured diclofenac concentrations in Reactor A.I (A), 
B.I (B), C.I (C), and D.I (D). 
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Average diclofenac removal has been observed as 24% in the anaerobic reactors 
performed properly. It is shown that adequate diclofenac removal has not been 
obtained in first generation anaerobic reactors such that diclofenac exhibit some 
resistance to anaerobic degradation. It is reported that no significant removal of 
diclofenac has been observed in upflow anaerobic sludge blanket (UASB) feeding 
with black water at 25ºC (de Graaff et al., 2011). However, diclofenac removal has 
been achieved as 26 % at 35ºC (Lahti and Oikari, 2011).  
Diclofenac removal by sorption onto sludge has been inadequate in anaerobic 
reactors. However, study on secondary treatment of WWtp has showed that 
diclofenac has been shown to persist in the aqueous phase of process. Diclofenac 
removal has been achived by biodegradation as 24% and by sorption onto sludge as 
7% (Khan and Ongerth, 2004). 
Sorption potential of diclofenac have been investigated on the sludge for the  Reactor 
A.I, B.I, and C.I. 176, 964 and 55 ng diclofenac have been detected in per g of sludge 
in Reactor A.I, B.I, and C.I (Table 4.9). Maximum sorption potential with 6% have 
been observed in Reactor B.I inoculated with anaerobic sludge of wwtp. Diclofenac 
has been existed in aqeous phase with low affinity to sorb to anaerobic sludge and 
low biodegradation rate in first generation anaerobic reactors.  
Table 4.9 : Fractions of diclofenac in Reactor A.I, B.I, and C.I. 
Reactor Biodegradation 
[%] 
Sorption onto 
sludge 
[%] 
Aqeous phase 
[%] 
A.I 22.67 2.04 75.29 
B.I 16.61 6.34 77.05 
C.I 31.20 0.98 67.82 
In order to eliminate sediment interruption, after 50 days incubation period a culture 
transfer was performed by diluting 100 mL of the Reactor A.I in anaerobic culture 
media (Reactor A.II). Reactor A.II inoculated as second generation reactor and have 
been fed during 150 days at 22ºC. During the operation the pH has been remained 
between 6.8 and 7.9 and the ORP has been observed nearly -231 mV.  
350 mg/L of COD have been introduced into the reactor by addition of glucose and 
methanol. 
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Until the fifth feeding cycle, low amount of biogas production hasbeen observed in 
Reactor A.II. as shown in Figure 4.8 because Reactor A.II has been inoculated with 
less amount of sludge, and the growth and acclimation of biomass has taken 
relatively long time. Biogas production has been increased after acclimation but not 
reached to the theoretical biogas production more likely due to presence of 
diclofenac. 
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Figure 4.8 : Biogas production performance of Reactor A.II. 
Reactor A.II has been amended with 1 µg/L diclofenac. During initial 56 days semi-
continuous feeding period, increasing diclofenac elimination has been observed. 
Approximately 35% of diclofenac removal has been achieved in Reactor A.II.   
While Reactor A.I hasbeen performed with averagely 24% of diclofenac removal, 
Reactor A.II has been performed with 35%.  
Higher aqueous phase diclofenac elimination has been observed in Alibeyköy A.II 
reactor that has been set up using the first generation reactor sludge as inoculum 
(Figure 4.9). It has been understood that biomass acclimation favored biodegradation 
of diclofenac. Similar to our findings, Carballa et al. (2007) have been reported the 
advantage of acclimation on diclofenac removal. 
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At the day 49, 720 mL of the culture have been taken from Albeyköy A.II as 
inoculum in order to setup batch assays and the reactor has been filled with fresh 
media and fed again. The higher decrease in the measured diclofenac concentration 
has been a result of this transfer for batch reactors setup.  
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Figure 4.9 : Theoretical and measured diclofenac concentrations in Reactor A.II. 
4.2.1 Culture developed at 35ºC 
Reactor F.I has been operated at 35ºC as a first generation anaerobic reactor. It has 
been fed weekly with glucose and methanol to provide 343 mg/L COD concentration 
in the reactor. 
Because, lower biogas productions have been obtained in first feeding cycle, 
additional 50 mL inoculums have been transferred to Reactor F.I at 10th day. After 
that, an increase in the biogas production was observed. 
Reactor F.I has been revealed continuous biogas production performance with 57 %  
methane portion (Figure 4.10).  
Reactor F.I has been fed with diclofenac weekly with 10 µg/L diclofenac 
concentration and kept at 35ºC in the dark. At the beginning of the culture 
development diclofenac removal was not achieved. However, after 70 days 
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acclimation period partial diclofenac degradation was observed in the reactor. In the 
reactor, maximum diclofenac removal efficiency has been 21% averagely. (Figure 
4.11). 
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Figure 4.10 : Biogas production in Reactor F.I. 
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Figure 4.11 : Theoretical and measured diclofenac concentrations in Reactor F.I. 
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Similar to our result, Lahti and Oikari (2011) has been reported 26 % of diclofenac 
elimination during the experiments with anaerobically digested sludge at 35ºC. 
Removal of diclofenac has also found as 60±18%  in mesophilic digestion at 37ºC 
(Carballa et al., 2007). 
Reactor F.I operated at 35ºC has not shown distinctive increase in  removal of 
diclofenac as 21 % in comparison to reactors operated at 22ºC including A.I, B.I, C.I, 
and D.I with 20, 21, 36, and 12%.  
4.3 Anaerobic Batch Assays  
4.3.1 Different diclofenac concentrations 
Four different concentrations including 0 (Control 1 and Control 2), 10, 50, 200 and 
1000 µg/L have been introduced to the developed fermentative-methanogenic culture 
to investigate the effect of diclofenac on fermentation, methanogenesis and 
diclofenac biodegradation. The cultures were monitored for 45 days incubation 
period.  
pH has been remained in the range of 7.2-8.0 and ORP has been measured in the 
range of -190 mV- -305 mV during the incubation for all culture series. 
Glucose and methanol were used as a carbon source, so 1000 mg/L COD resulting 
from both glucose and methanol has been introduced into the all culture series. 
Theoretical methane productions according to the COD introduced have been 
calculated as 62 mL in serum bottles (180 mL liquid volume). Also diclofenac has 
been a carbon source resulted in 1.8 mg/L COD in culture series with 1000 µg/L. It 
has been negligible value in terms of methane production (approximately 0.11 mL). 
Control 1 which have been inoculated with only culture from Reactor A.II have been 
produced 62 mL of methane as shown in Figure 4.12. However, other culture series 
that inoculated with culture from Reactor A.II and E.I have been exceeded this value. 
The reason of excess methane production compared to the theoretical value has been 
the additional COD coming from culture of Reactor E.I. Approximately 100 mg/L of 
COD has been transferred to culture series with culture from Reactor E.I. 
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Despite no significant change in methane production has been seen in lower 
concentrations such as 10, 50 and 200 µg/L, approximately 8 mL of decrease has 
been observed in the culture amended with 1000 µg/L diclofenac (Figure 4.12).  
A
Time [day]
0 10 20 30 40
C
H
4
 p
ro
d
u
c
ti
o
n
 [
m
L
]
0
20
40
60
80
100
B
Time [day]
0 10 20 30 40
C
O
2
 p
ro
d
u
c
ti
o
n
 [
m
L
]
0
5
10
15
20
25
30
35
Control 1 
Control 2 
10 µg/L
50 µg/L
200 µg/L
1000 g/L
Control 1 
Control 2 
10 µg/L
50 µg/L
200 µg/L
1000 g/L
 
Figure 4.12 : Methane (A) and carbondioxide (B) production in batch test with     
different diclofenac concentrations. 
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It has also found that diclofenac caused severe inhibition on methanogenic activity at 
high concentrations according to a research where concentrations ranging from 0 up 
to 400 mg/L have been tested (Fountoulakis et al., 2004). Additionally, the 
concentration of VSS decreased at the end of 30 days incubation period. 
Carbon dioxide profiles have showed that diclofenac concentration has not effect 
carbondioxide production. All culture series except Control 1 have been produced 
averagely 28-29 mL of carbon dioxide as shown in Figure 4.12. 
Volatile suspended solids (VSS) concentrations have been decreased through the 
operation period in all culture series except Control 1, which has not been amended 
with diclofenac as shown in Figure 4.13. 
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Figure 4.13 : Suspended solids behaviour in batch anaerobic test of different 
diclofenac concentrations. 
COD introduced into culture series in the form of glucose have converted into the 
VFAs. Acetic acid, propionic acid, and isobutyric acid have been produced in all 
culture series. 
Due to unconsumed VFAs coming from culture of Reactor E.I, VFAs concentration 
in Control 2, 10 µg/L, 50 µg/L, 200 µg/L, and 1 mg/L of culture series have not been 
zero at the time 0 as shown in Figure 4.14. Initial VFA concentration was determined 
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as 20 mg/L in all of the reactors except Control 1 that was not amended with the 
culture from Reactor E.I. 
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Figure 4.14 : Acetic (A) and propionic acid (B) concentration in anaerobic batch test 
with different diclofenac concentrations. 
VFAs in all of the reactors have been consumed completely at the end of 15 days 
incubation period as shown in Figure 4.14. The VFAs production and consumption 
profiles were very similar in all of the reactors indication no interference of 
diclofenac on fermentative microorganisms. 
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As shown in the Figure 4.15, elimination of diclofenac has been achived between 18 
and 54 %, and higher removal efficiencies has been observed in higher 
concentrations of diclofenac. Moreover, a quantitative relationship has been 
recognized between diclofenac removal and VFAs. In 15 day period of batch set in 
other words when VFAs have been existed in the reactor, diclofenac removal process 
has been occurred and in the absence of VFAs diclofenac degradation has been 
stopped.  
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Figure 4.15 : Diclofenac concentrations in anaerobic batch reactors with different 
diclofenac concentrations.  
74 
In most of the reactors an increase in the diclofenac concentration has been observed 
right after the complete degradation of VFAs in the system. This observation can be 
explained by the metabolism or/and transformation products converted back to the 
parent compound in the lack of VFA in other words substrate. 
Acidic polar pharmaceuticals have been removed mostly by cometabolic 
transformation (Quintana et al., 2005). Diclofenac has been used as cometabolic 
substrate in the presence of readily biodegradable substrate such as glucose, acetate 
etc. that microorganisms has gained energy from. Cometabolic substrate 
transformation capacity of microorganism has been related with the energy yield and 
the reductive force regeneration potential of microorganisms, derived from substrates 
(Chang and Alvarez-Cohen, 1995). In the presence of readily biodegradable 
substrate, cometabolic biotransformation of chlorinated solvents that diclofenac 
molecule have had in its structure can be occurred. 
No reports have been present about cometabolic transformation of diclofenac in 
anaerobic treatment system. However, Lahti and Oikari (2011) have been studied on 
aerobic degradation of diclofenac in the presence and absence of readily 
biodegradable substrate as acetate. The removal efficiencies of diclofenac have been 
observed in the range of 1-13% in the presence of acetate. In comparison to that, the 
concentration of diclofenac without acetate has been remained unchanged. 
4.3.2 Different temperatures 
Experiments with four culture series with different temperature have been conducted 
to observe temperature effect on diclofenac degradation at 10, 22, 35, and 45ºC. 
Culture series have been incubated for 70 days. The cultures have been fed twice 
during the acclimation period to supply sufficient electron donor. The second feeding 
has been performed at the 34th day of the incubation. 
During the first feeding period pH and ORP values of culture series have varied in 
the range of 7.0-8.5 and -120 mV – -350 mV while they have varied in the range of 
6.9-8.0 and -100 mV--290 mV during the second feeding, respectively. 
For each feeding, 1000 mg/L COD have been added to culture series in the form of 
glucose and methanol from stock solution. According to COD value, theoretical 
methane production have been calculated as 62 mL.  
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Figure 4.16 : Diclofenac and VFA concentrations in culture series with different diclofenac concentrations
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 However, culture series except 10ºC have produced more than theoretical value. Because, 
culture from Reactor E.I have provide approximately 200 mg/L COD to culture series. This 
excessive 200 mg/L of COD has showed theoretically itself as 13 mL of methane gas. 
For each feeding, culture series at 10ºC have lower methane production with 15 mL as shown 
in Figure 4.17 because temperature sensitive methanogenic bacteria have not performed at 
this temperature. 
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Figure 4.17 : Methane (A) and carbondioxide (B) production in batch test with different 
temperatures. 
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Methane production profiles have showed that rate of methanogenesis has increased with 
increasing temperature. For first feeding, methane production profile has also showed that 
methane production was increased with increasing temperature. For second feeding, culture 
series at 35 and 45ºC has shown higher methane production with respect to 22ºC because 
methanogenic activity has been increased with increased temperature and long acclimation 
period. 
Carbon dioxide production had same behavior with methane production. Culture series at 
10ºC have shown the less production with 8 and 14 mL for the first and the second feeding 
due to lower methanogenic activity at this temperature. For other culture series, carbon 
dioxide production has been increased with increasing temperature as shown in Figure 4.17. 
1000 mg/L of COD introduced into culture series in the form of glucose and methanol have 
converted to VFAs. Acetic acid and propionic acid have been produced in culture series. 
VFA produced by acetogens have not consumed by methanogens and accumulated in culture 
at 10ºC as shown in Figure 4.18. 
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Figure 4.18 : Acetic acid concentration at 10ºC. 
Due to the carbon coming from culture of Reactor E.I, VFA concentration in each culture 
series at different temperatures have not been zero at the time 0. VFA consumption rate has 
been increased with increased temperature. 
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VFA levels at time 0 have not been same in all temperatures because initial one day 
incubation has been performed to acclimate biomass to relevant temperature before substrate 
addition where some of the VFAs has been consumed. 
For the cultures incubated at 35ºC and 45ºC, at first feeding cycle the type of VFA which 
have been mainly produced and accumulated was propionic acid whereas in the second 
feeding it has been acetic acid as shown in Figure 4.19. 
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Figure 4.19 : Acetic acid (A) and propionic acid (B) concentration in anaerobic batch test 
with different temperatures. 
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In the first feeding cycle VSS concentration has been tend to increase until 15 days. At the 
day 32, depletion on VSS concentration has been observed due to endogenous respiration in 
the absence of carbon source. However, VSS concentration has showed an increasing trend 
throughout the second feeding as shown in Figure 4.20. 
 
Figure 4.20 : VSS concentration in anaerobic batch test with different temperature. 
For the first feeding cycle, diclofenac removal efficiency has not changed considerably with 
temperature as shown in Figure 4.19. Diclofenac removal efficiency has been obtained as 
19%, 19%, 27%, and 22 % at 10, 22, 35, and 45ºC, respectively. 
Carballa et al. (2007 and 2008) have been studied on temperature effect on  elimination of 
diclofenac with  mesophilic and thermophilic anaerobic digester at 37ºC and 45ºC and  with 
20 day and 10 day  of SRT,  respectively. They observed that elimination of diclofenac has 
been occurred after sludge adaptation and acclimation result in presence of more active 
microbial population.  Removal of diclofenac has been increased 60±18 and 73±9% after 
sludge adaptation at 37ºC and 45ºC, respectively. However, no significance influences of 
temperature has been observed. It has also been reported that diclofenac removal efficiency in 
WWTP has been varied between 9 and 41% without any significant change with temperature 
(Oosterhuis et al., 2013). 
 
Time [days]
V
S
S
  
[m
g
/L
]
0
200
400
600
800
1000
1200
10
o
C
22
o
C
35
o
C
45
o
C 
0 18 32 34 57 70
first feeding second feeding
80 
Time [day]
0 5 10 15 20 25 30 35
D
ic
lo
fe
n
a
c
 [

g
/l
L
]
0
20
40
60
10 oC CONTROL
10 oC REACTOR
Time [day]
0 5 10 15 20 25 30 35
D
ic
lo
fe
n
a
c
 [
m
g
/l
L
]
0
20
40
60
20 oC CONTROL
20 oC REACTOR
Time [day]
0 5 10 15 20 25 30 35
D
ic
lo
fe
n
a
c
 [

g
/l
L
]
0
20
40
60
35 oC CONTROL
35 oC REACTOR
Time [day]
0 5 10 15 20 25 30 35
D
ic
lo
fe
n
a
c
 [

g
/l
L
]
0
20
40
60
45 oC CONTROL
45 oC REACTOR
 
Figure 4.21 : Diclofenac concentrations in batch assay with different temperature for      first   
feeding. 
However, after second feeding, diclofenac elimination has not been observed in significant 
extend as shown in Figure 4.22. In the reactors, fluctuations and increasing trend in diclofenac 
concentration have been observed with negative removal. The negative removal can be 
explained by the formation of the unmeasured by products of bacterial metabolism which has 
been converted back to parent compound of diclofenac. 
It has been also observed that diclofenac removal in control of each culture series at relevant 
temperature has shown similar trend with no depletion around 50 µg/L. It has been 
understood that diclofenac elimination achieved in culture series has been achieved by 
biodegradation without photodegradation and abiotic degradation.  
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Figure 4.22 : Diclofenac concentrations in batch assay with different temperature for first and 
second feeding, 
4.3.3 Different biomass concentration 
Four culture series with different initial biomass concentration including 25, 50, 75, and 100 
% have been conducted to observe effect of initial biomass concentration  on diclofenac 
degradation. Culture series have been operated in total 33 days.  
During the operation period pH and ORP values of culture series have varied in the range of 
6.6-7.2 and -117 mV – -222 mV during the operation period. 
1000 mg/L COD have been added to culture series in the form of glucose and methanol from 
stock solution. According to COD value, theoretical methane gas productions have been 
calculated as 62 mL. However, culture series have produced more than theoretical value. 
Because, culture from Reactor E.I have provide approximately 130, 94, 73, and 47 mg/L COD 
82 
to culture series with 100, 75, 50, and 25 % of biomass, respectively. This excessive COD 
have showed theoretically itself as 8, 6, 5, and 3 mL of methane gas as shown in Figure 4.23. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 : Methane (A) and carbondioxide (B) production in batch test with different 
biomass concentrations. 
Methane production profiles have shown that rate of methanogenesis has increased with 
increased initial biomass concentrations. Methane content has been increased with time and 
reached steady state condition. At the end of the operation methane content has been 
measured  in GC as 70, 71, 72, and 72 % culture series with 100, 75, 50, and 25 % of 
biomass, respectively. 
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Figure 4.24 : Acetic acid (A) and propionic acid (B) concentration in anaerobic batch test 
with different biomass concentrations. 
Carbon dioxide production has had same behavior with methane production. It has been 
increased with increasing initial biomass concentration as shown in Figure 4.23. 
Due to carbon coming from culture of Reactor E.I, VFA concentration in each culture series 
at different biomass concentrations have not been zero at the time 0. VFA consumption rate 
has been increased with increased initial concentrations as shown in Figure 4.24. 
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100, 75, 50 and 25% of biomass have been planned to add four culture series. However, the 
measurements have shown 100, 89, 59, and 36% of biomass at the day of  0. 
VSS concentration has been decreased at the end 33 days of incubation period due to the 
endogenous decay. 
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Figure 4.25 : Suspended solids behaviour in batch anaerobic test of different biomass 
concentrations 
Until the day 16, diclofenac removal efficiency has been obtained as 26, 23, 21, and 21%  in 
the culture series of 100, 75, 50, and 25 % biomass, respectively. After the day 16, diclofenac 
concentration has tended to increase in lack of VFA as shown in Figure 4.26. The reason of 
this has been explained by metabolism or transformation products formed by bacteria 
throughout the processes have been converted back to parent compound (Jelic et al., 2011). 
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Figure 4.26: Diclofenac concentrations in batch assay with different biomass concentrations. 
4.3.4 Different carbon source 
In order to investigate effect of different carbon source on diclofenac removal efficiency, 
culture series was fed with acetate as electron donor. 
During the first operation period pH and ORP values of culture series have varied in the range 
of 6.96-7.13 and -167 mV – -233 mV, respectively.  
For first feeding period, 1248 mg/L COD have been added to culture series in the form of 
sodium acetate and methanol from stock solution. According to COD value, theoretical 
methane production have been calculated as 79 mL for first feeding. However, reactor has 
produced more than theoretical value. Because, culture from Reactor E.I have provided extra 
COD to reactor. For second feeding, the reactor has fed with only sodium acetate and 578 
86 
mg/L COD have been introduced to reactor. According to COD value, theoretical methane 
production have been calculated as 36 mL for second feeding 
Culture series with acetate feeding has shown higher methane production rate and consumed 
the COD in shorter time compared to the culture series with glucose (Figure 4.27). At the end 
of the operation culture series with acetate feeding has reached 80 % of methane content in 
the biogas. It has been higher than the value measured in culture series fed with glucose. 
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Figure 4.27 : Methane and carbon dioxide production in acetate fed culture series. 
Due to carbon coming from culture of Reactor E.I, VFA concentration have not been zero at 
the time 0. Near the day 8, acetate has been consumed completely in the system as shown in 
Figure 4.28. 
Diclofenac removal efficiency has observed 25% at the day 8 as shown in Figure 4.29. After 
that, diclofenac concentration has been increased with decreasing acetate concentration. 
Culture series fed with glucose have performed better diclofenac elimination with respect to 
culture series fed with acetate.  
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                 Figure 4.28 : Acetic acid concentrations in culture series with acetate feeding. 
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Figure 4.29 : Diclofenac concentration in culture series with acetate feeding. 
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5.  CONCLUSION AND RECOMMENDATIONS 
According to sampling campaigns carried out in WWTP in 4 seasons of the year, maximum 
diclofenac concentration of 1376 µg/L has been detected in winter due to higher consumtion 
of diclofenac with increasing illnesses in colder months. Maximum removal efficiency of 
diclofenac has been found as 51% in summer with increasing ambient temperature. 
Diclofenac removal profile has shown similar trend with nitrogen removal profile. Both has 
shown same increasing and decreasing pattern throughout the year. It is observed that 45 and 
27 % of diclofenac removal have been achieved by secondary treatment in summer and 
winter, respectively. Operation efficiency of secondary treatment as activated sludge process 
with A2O has been correlated with diclofenac elimination, because diclofenac removal has 
been decreased with decreasing TKN, NH3, and TP removal. 
Laboratory experiments have shown that removal of diclofenac has not completely achieved 
under anaerobic conditions. Diclofenac has shown significant resistance to biodegradation. It 
has also been tend to remain in aqeous phase instead of sorption onto the sludge. Maximum 2 
% of diclofenac has remained in sludge phase whereas most of them have been occurred in 
aqueous phase. Anaerobic reactors operated at 22ºC as first generation reactor has been 
performed with 13 - 31 % diclofenac removal. Due biomass adaptation has been enchanced 
biodegradation of diclofenac, second generation anaerobic  reactors at 22ºC has been achieved 
better removal efficiency with respect to first generation reactors. Also, 21 % of diclofenac 
elimination has been obtained in anaerobic reactor operated at 35ºC.  
Among 10, 50, 200, and 1000 µg/L of diclofenac concentrations applied in batch assays, 1000 
µg/L of diclofenac concentrations has revealed very low inhibitory effects on methanogens 
that has shown itself decreasing in methane production and VSS concentrations. Diclofenac 
concentration has been tend to increase right after the complete consumption of VFAs.  
Even at different temperatures, diclofenac removal was not achieved under abiotic conditions 
reflecting microbial activity importance on its degradation. Diclofenac removal has been 
observed in the range of 19-27%. No relation has been found between temperature and 
diclofenac removal efficiency. In addition, diclofenac removal efficiency has tended to 
90 
increase with an increasing initial biomass concentration at the first 3 days of the operation 
then reactors have been shown similar removal efficiencies in the presence of substrate.  
Studies have shown that diclofenac has not been completely removed inconventional 
biological treatment processes used by municipal wwtps. Conventional WWTPs needs to be 
upgraded with tertiary treatment process to treat this kind of emerging micropollutants. 
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